Super Formulário Probióticos Bifórmula PDF

Índice
Introdução_________________________________________________________ 05
Probióticos nas Doenças Intestinais e do Sistema Digestivo__________________ 07
Constipação Intestinal Crônica__________________________________________ 08
Diarreia Associada a Antibióticos_________________________________________ 09
Diarreia Aguda em Crianças____________________________________________ 10
Cólica Infantil_________________________________________________________ 11
Síndrome do Intestino Irritável___________________________________________ 12
Doença de Crohn_____________________________________________________ 14
Colite Ulcerativa______________________________________________________ 15
Idosos Submetidos à Cirurgia Colorretal___________________________________ 17
Infecção por H. pylori__________________________________________________ 18
Formulações_________________________________________________________ 20
Formulário 1 - Constipação / Diarreia / Cólica Infantil_________________________ 21
Formulário 2 - Síndrome do Intestino Irritável_______________________________ 22
Formulário 3 - Doença de Crohn e Colite Ulcerativa_________________________ 23
Formulário 4 - Terapia Probiótica Pós-operatória e Infecção por H. pylori________ 24
Probióticos nas Doenças Metabólicas____________________________________ 25
Hipercolesterolemia___________________________________________________ 26
Dislipidemia em Crianças______________________________________________ 28
Obesidade__________________________________________________________ 29
Doença Hepática Gordurosa Não-acoólica________________________________ 31
Formulações_________________________________________________________ 32
Formulário 1 - Hipercolesterolemia / Dislipidemia___________________________ 33
Formulário 2 - Obesidade / DHGNA______________________________________ 34
Probióticos e Tratamento de Condições Cutâneas__________________________ 35
Tratamento da Acne___________________________________________________ 36
Dermatite Atópica_____________________________________________________ 38
BIFÓRMULA FARMÁCIA DE MANIPULAÇÃO – MOEMA: Av. Ibirapuera, 1898 - SP - Tel: 5051-2601 - Fax: 5052-5114 - WhatsApp 11 2
97550-0995 - VILA MARIANA: Av. Cons. Rodrigues Alves, 203 - SP - Tel: 5575-0765 - Fax: 5575-4613 - WhatsApp 11 97510-4000
atendimentomedico@biformula.com.br - www.biformula.com.br
Siga-nos nas redes sociais: Facebook/Biformula - Instagram@biformula
Dermatite Atópica Infantil_______________________________________________ 39
Fotoproteção________________________________________________________ 41
Fotoenvelhecimento___________________________________________________ 42
Peles Reativas________________________________________________________ 43
Formulações_________________________________________________________ 44
Formulário 1 - Tratamento da Acne_______________________________________ 45
Formulário 2 - Dermatite Atópica em Adultos e Crianças______________________ 46
Formulário 3 - Fotoproteção / Anti-ageing / Peles Reativas____________________ 47
Probióticos e Doenças Osteoarticulares___________________________________ 48
Osteoporose_________________________________________________________ 49
Artrite Reumatoide____________________________________________________ 50
Formulações_________________________________________________________ 52
Formulário 1 - Osteoporose e Artrite Reumatoide___________________________ 53
Probióticos e Doenças Alérgicas_________________________________________ 54
Rinite Alérgica Persistente______________________________________________ 55
Rinite Alérgica Sazonal_________________________________________________ 56
Alergia em Pacientes Rinopáticos________________________________________ 57
Asma / Rinite Alérgica em Crianças_______________________________________ 58
Alergia ao Leite em Crianças____________________________________________ 60
Suplementação Pré-natal_______________________________________________ 61
Formulações_________________________________________________________ 62
Formulário 1 - Rinite Alérgica / Rinopatia___________________________________ 63
Formulário 2 - Prevenção / Tratamento de Alergias em Crianças_______________ 64
Probióticos e Alterações Urogenitais______________________________________ 65
Vaginose Bacteriana___________________________________________________ 66
Candidíase Vulvovaginal_______________________________________________ 68
Atrofia Vulvovaginal____________________________________________________ 69
Alteração da Microbiota Vaginal__________________________________________ 70
Formulações_________________________________________________________ 71
Formulário 1 - Vaginose Bacteriana / Candidíase Vulvovaginal_________________ 72
Formulário 2 - Atrofia Vulvovaginal / Restauração da Microbiota Local___________ 73
Probióticos e Neurologia_______________________________________________ 74
Depressão__________________________________________________________ 75
Formulações_________________________________________________________ 76
Depressão__________________________________________________________ 77
Abstracts____________________________________________________________ 78
Probióticos
Definição e Aplicações Clínicas
O termo "probiótico" deriva do grego e significa "pró-vida", sendo o antônimo de
antibiótico, que significa "contra a vida".
Autores consideram que o termo probiótico se aplica a culturas únicas ou

mistas de micro-organismos que, administrados a animais ou humanos,
produzem efeitos benéficos no hospedeiro por incremento das propriedades
da microbiota nativa.
Principais Características dos Probióticos
 Devem estar em quantidades adequadas, alterando assim a microbiota própria

das mucosas por implantação ou colonização de um sistema do hospedeiro;
 Devem ser inócuos;
 Devem manter-se viáveis por longo tempo durante a estocagem e transporte;
 Devem tolerar o baixo pH do suco gástrico e resistir à ação da bile e das
secreções pancreática e intestinal;
 Não devem transportar genes transmissores de resistência à antibióticos;
 Devem Possuir propriedades antimutagênicas e anticarcinogênicas.
Aplicações e Mecanismos de Ação
Tratamento e prevenção de doenças, regulação da

microbiota intestinal, distúrbios
do metabolismo gastroinstestinal e
Principais Aplicações dos imunomodulação
Probióticos
Mecanismos de Ação
Alteração do pH intraluminal;
Produção de substâncias com atividade antimicrobiana;
Competição por nutrientes;
Competição por receptores intestinais para adesão;
Efeito imunomodulador;
Restauração da permeabilidade intestinal.
Probióticos nas
Doenças Intestinais e do
Sistema Digestivo
Constipação Intestinal Crônica
Iogurte Simbiótico Melhora o Tempo de Trânsito
Intestinal
Objetivo do Estudo
Magro et al. (2014) conduziram um estudo que teve como objetivo avaliar os efeitos da
suplementação de um iogurte contendo uma mistura simbiótica sobre o trânsito
intestinal em indivíduos que apresentavam constipação intestinal crônica.
Indivíduos com constipação crônica foram selecionados e divididos em 2 grupos

para receber durante 14 dias:
Grupo 1 - Tratamento
Consumo diário de um iogurte contendo: Grupo 2
Lactobacillus acidophilus - 1x109 UFC
Iogurte sem adição de probióticos
Bifidobacterium lactis - 1x109 UFC
Polidextrose - 3,6 g
Resultados e Conclusão
 A resposta clínica favorável foi avaliada através do escore Agachan, o qual

apresentou redução significativa ao final de estudo, sendo superior no grupo que
recebeu o iogurte enriquecido com a mistura de probióticos + polidextrose;
 Os indivíduos do grupo tratamento também apresentaram redução do tempo de

trânsito intestinal ao final da intervenção, em comparação com os indivíduos do
grupo 2.
A administração de um iogurte enriquecido com uma mistura de probióticos +

prebióticos é eficaz na melhora do trânsito intestinal, reduzindo a severidade da
constipação intesntinal crônica.
Referências
Magro DO1, de Oliveira LM, Bernasconi I, Ruela Mde S, Credidio L, Barcelos IK, Leal RF, Ayrizono Mde L, Fagundes JJ, Teixeira Lde B, Ouwehand AC, Coy CS. Effect of yogurt containing
BIFÓRMULA
polydextrose, LactobacillusFARMÁCIA DE MANIPULAÇÃO
acidophilus NCFM and Bifidobacterium– lactis
MOEMA: HN019:Av. Ibirapuera,double-blind,
a randomized, 1898 - SPcontrolled
- Tel: 5051-2601 - Fax:constipation.
study in chronic 5052-5114 Nutr- WhatsApp 11
J. 2014 Jul 24;13:75. doi: 7
10.1186/1475-2891-13-75.
Diarreia Associada a Antibióticos
Lactobacillus reuteri Reduz a Ocorrência de
Diarreia Decorrente do Uso de Antibióticos
Objetivo do Estudo
Cimperman et al. (2011) conduziram um estudo que teve como objetivo avaliar a eficácia
da administração de probióticos sobre a ocorrência de diarreia associada à
antibioticoterapia em adultos hospitalizados.
Nesse estudo, 31 pacientes sob terapia com antibióticos foram selecionados

para receber durante 4 semanas:
Grupo 1 (n=13)
Grupo 2 (n=10)
Lactobacillus reuteri
Placebo
1x109 UFC, 2 vezes ao dia
Entre os parâmetros avaliados, estavam a consistência das fezes, a frequência de evacuações e

sintomas gastrointestinais, que foram monitorados durante o estudo e por mais 2 semanas.
 Os principais problemas de saúde apresentados pelos pacientes eram:

pneumonia, abscesso, doença pulmonar obstrutiva crônica e bronquite;
 Os pacientes tratados com L. reuteri apresentaram frequência de diarrea
significativamente inferior aos tratados com placebo (7,7% vs. 50%,
respectivamente);
 Não foram observadas diferenças com relação à frequência e intensidade de
sintomas gastroinstestinais.
A suplementação com probióticos é uma estratégica segura e eficaz para prevenir a

ocorrência de diarreia entre pacientes hospitalizados sob terapia com antibióticos.
Referências
Cimperman L1, Bayless G, Best K, Diligente A, Mordarski B, Oster M, Smith M, Vatakis F, Wiese D, Steiber A, Katz J. A randomized, double-blind, placebo-controlled pilot study of
Lactobacillus reuteri ATCC 55730 for the prevention of antibiotic-associated diarrhea in hospitalized adults. J Clin Gastroenterol. 2011 Oct;45(9):785-9. doi:
10.1097/MCG.0b013e3182166a42.
Diarreia Aguda em Crianças
Lactobacillus casei Reduz o Tempo de Duração
da Diarreia e Melhora a Consistência das Fezes
Objetivo do Estudo
Aggarwal et al. (2014) conduziram um estudo que teve como objetivo avaliar a eficácia e
a segurança da administração de probióticos em crianças acometidas pela diarreia
aguda.
Um total de 2000 crianças com diarreia aguda aquosa, com idades entre 6
meses e 5 anos, foram divididas em 2 grupos para receber por 5 dias:
Grupo 1
Grupo 2
Lactobacillus casei
Tratamento padrão isolado
10 x 109 UFC/dia + Tratamento antidiarreico padrão
 A duração média da diarreia foi significativamente inferior no grupo tratado com

probióticos;
 Também houve melhora mais considerável e mais rápida da consistência das
fezes no grupo I;
 Outro resultado observado foi redução do número de evacuações diárias no
grupo que recebeu probióticos.
Este estudo permitiu concluir que a suplementação com probióticos é uma estratégia
eficaz para redução da duração e da instensidade da diarreia aguda em crianças.
Referências
Aggarwal S, Upadhyay A1, Shah D, Teotia N, Agarwal A, Jaiswal V. Lactobacillus GG for treatment of acute childhood diarrhoea: an open labelled, randomized controlled trial. Indian J Med
Res. 2014 Mar;139(3):379-85.
Cólica Infantil
Lactobacillus reuteri Reduz a Cólica Intestinal em
Crianças
Objetivo do Estudo
Um estudo conduzido por Chau et al. (2015) teve como objetivo avaliar os efeitos da
suplementação com probióticos no tratamento da cólica em lactentes.
Um total de 52 crianças com cólica, de acordo com o critério Wessel

modificado, foram divididas em 2 grupos para receber, por 21 dias:
Grupo 1 (n=24)
Grupo 2 (n=28)
Placebo
1x108 UFC/dia
Para avaliação dos resultados, foi verificado o choro das crianças e também o nível de
agitação, além da realização de questionários respondidos pelas mães.
 As crianças tratadas com probióticos apresentaram redução do choro e da

agitação em comparação com as crianças tratadas com placebo;
 No dia 21, uma porção significativamente superior de crianças do grupo I
apresentou resposta ao tratamento, com redução ≥50% do tempo de choro em
comparação com o grupo II;
 O tratamento se mostrou seguro.
A suplementação com probióticos se mostrou uma nova estratégia para redução das
cólicas intestinais em lactentes, reduzindo o choro e a agitação característicos.
Referências
Chau K1, Lau E2, Greenberg S3, Jacobson S4, Yazdani-Brojeni P5, Verma N5, Koren G6. Probiotics for infantile colic: a randomized, double-blind, placebo-controlled trial investigating
Lactobacillus reuteri DSM 17938. J Pediatr. 2015 Jan;166(1):74-8. doi: 10.1016/j.jpeds.2014.09.020. Epub 2014 Oct 23.
Síndrome do Intestino Irritável
Probióticos Aliviam os Sintomas, Melhorando a
Consistência das Fezes
Objetivo do Estudo
Cha et al. (2012) conduziram um estudo que teve como objetivo avaliar um pool de
probióticos na redução dos sintomas do intestino irritável e na composição da
microbiota fecal em pacientes com intestino irritável com predominância de diarreia.
Um total de 50 pacientes com síndrome do intestino irritável com

predominância de diarreia foi dividido em 2 grupos para receber por 8
semanas:
Grupo 1 - Tratamento
Pool contendo Lactobacillus acidophilus,
Lactobacillus plantarum, Lactobacillus rhamnosus, Grupo 2 - Controle
Bifidobacterium breve, Bifidobacterium lactis, Placebo
Bifidobacterium longum e Streptococcus
thermophilus 2,5 x 1010 UFC
 A proporção de pacientes com alívio dos sintomas foi significativamente maior no

grupo que recebeu probióticos (p<0,05);
 A proporção de “respondedores” também foi significativamente maior no grupo
que recebeu probióticos (48% vs. 12%);
 A consistência das fezes melhorou significativamente no grupo probiótico, assim
como a qualidade de vida;
 A composição fecal foi melhor no grupo probiótico.
O pool de probióticos foi efetivo em prover alívio dos sintomas gerais da síndrome do
intestino irritável e melhorou a consistência das fezes. Os efeitos terapêuticos dos
probióticos estão associados com a estabilização da microbiota intestinal.
Referências
Ki Cha B, Mun Jung S, Hwan Choi C, Song ID, Woong Lee H, Joon Kim H, Hyuk J, Kyung Chang S, Kim K, Chung WS, Seo JG. The effect of a multispecies probiotic mixture on the
symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial..J Clin Gastroenterol. 2012 Mar;46(3):220-7. doi:
10.1097/MCG.0b013e31823712b1.
Outras Evidências Encontradas
Pool de Probióticos Reduz os Sintomas da SII em 68% dos Pacientes
Um estudo conduzido por Yoon et al. (2014) teve como objetivo avaliar os efeitos da
suplementação de multiespécies de probióticos nos sintomas da SII.
Para isso, 49 pacientes com diagnóstico de SII foram randomizados em 2 grupos para
receber por 4 semanas:
Grupo 1 (n=25)
Mistura de Probióticos
(Bifidobacterium longum, B. bifidum, B. lactis, Lactobacillus Grupo 2 (n=24)
acidophillus, L. rhamnosus e Streptococcus thermophilus) Placebo
2 vezes ao dia.
De acordo com os resultados, a suplementação com probióticos promoveu redução da

dor abdominal e do inchaço, promovendo alívio nos sintomas da SII após 4 semanas de
tratamento.
Outras Evidências Encontradas
Existem muitos estudos clínicos que investigam os benefícios terapêuticos dos

probióticos em pacientes com SII (Lee e Bak, 2011).
Dose
Autores Probióticos Duração Principais Resultados
(UFC/ml)
Sinn et al., Lactobacillus Redução significativa na dor
2,0 x 109 4 semanas
(2008) acidophilus abdominal e no desconforto.
Niedzielin et Melhora dos sintomas da SII (dor,
L. plantarum 5,0 x 107 4 semanas
al., (2001) constipação, diarreia e flatulência).
Nobaek et al., Melhora da flatulência em relação
L. plantarum 5,0 x 107 4 semanas
(2000) ao placebo: 44% vs. 18%.
Significativa redução na
severidade e no número de dias
Williams et al., L.
2,5 x 1010 8 semanas com dor. Melhora da qualidade de
(2009) acidophilus
vida quando comparado com o
placebo.
Alberda et al., 1,0 x 108, 2 A constipação reduziu apenas no
L. reuteri 1 semana
(2007) vezes ao dia grupo tratado com L. reuteri.
Referências
Yoon JS1, Sohn W, Lee OY, Lee SP, Lee KN, Jun DW, Lee HL, Yoon BC, Choi HS, Chung WS, Seo JG. Effect of multispecies probiotics on irritable bowel syndrome: a randomized, double-
blind, placebo-controlled trial. J Gastroenterol Hepatol. 2014 Jan;29(1):52-9. doi: 10.1111/jgh.12322.
Lee BJ, Bak YT. Irritable bowel syndrome, gut microbiota and probiotics. J Neurogastroenterol Motil. 2011 Jul;17(3):252-66.
Doença de Crohn
Associação Simbiótica é Eficaz na Indução da
Remissão da Doença
Objetivo do Estudo
Fujimori et al. (2007) conduziram um estudo que teve como objetivo avaliar a eficácia da
suplementação associada entre probióticos e prebióticos (simbiótico) no tratamento da
Doença de Crohn ativa.
Um total de 10 pacientes com Doença de Crohn, cujos principais sintomas eram

diarreia e dor abdominal, e que não obtiveram resposta com o tratamento
padrão com aminossalicilatos e prednisolona foram selecionados para receber
por aproximadamente 1 ano
Pool Simbiótico
Probiótico em alta dose (75 x 109 UFC de
Lactobacillus e Bifidobacterium)
+
Psyllium (10 g/dia)
 A duração do estudo foi de 13 +/- 4,5 meses;

 Sete pacientes apresetaram melhoras clínicas significativas após o uso da
terapia combinada;
 O Crohn´s Disease Activity Index (CDAI) e o International Organization for the
Study of Inflammatory Bowel Disease (IOIBD) apresentaram redução significativa
após a terapia;
 Dois pacientes descontinuaram o tratamento com a prednisolona, enquanto
quatro pacientes reduziram a administração;
 Não foram observados eventos adversos sérios após a administração da terapia
simbiótica.
O pool simbiótico (composto por altas doses de probióticos + prebiótico) foi seguro e
eficaz na redução da severidade da Doença de Crohn, reduzindo a necessidade de
anti-inflamatórios esteroidais.
Referências
Fujimori S1, Tatsuguchi A, Gudis K, Kishida T, Mitsui K, Ehara A, Kobayashi T, Sekita Y, Seo T, Sakamoto C. High dose probiotic and prebiotic cotherapy for remission induction of active
Crohn's disease. J Gastroenterol Hepatol. 2007 Aug;22(8):1199-204.
Colite Ulcerativa
Lactobacillus rhamnosus é Eficaz na Manutenção
da Remissão da Doença
Objetivo do Estudo
Um estudo conduzido por Zocco et al. (2006) teve como objetivo avaliar a eficácia de
Lactobacillus rhamnosus isolado ou em combinação com a mesalazina versus
mesalazina como tratamento de manutenção da remissão da colite ulcerativa.
Um total de 187 pacientes com colite ulcerativa foram selecionados para

participar do estudo e randomizados para receber:
Grupo I (n=65) Grupo II (n=60) Grupo III (n=62)

Lactobacillus rhamnosus 18x109 Mesalazina 800 mg Lactobacillus rhamnosus 18x109
UFC/dia, dividido em 2 tomadas 3 vezes ao dia UFC/dia + Mesalazina 2400 mg/dia
 O índice de atividade da doença, endoscopia e escores histológicos foram determinados no

mês 0, 6 e 12 e em casos de recaída;
 O desfecho primário foi avaliar a remissão sustentada.
 A análise global não mostrou nenhuma diferença significativa na taxa de recaída

em 6 e 12 meses entre os três grupos de tratamento;
 No entanto, o tratamento com L. rhamnosus isolado mostrou ser mais eficaz do

que o tratamento padrão com mesalazina em prolongar o tempo de remissão.
Os resultados do estudo demonstraram que a suplementação de L. rhamnosus parece ser

segura e eficaz para manter a remissão da doença em pacientes com colite ulcerativa e
que poderia representar uma boa opção terapêutica para a prevenção da recaída neste
grupo de pacientes.
BIFÓRMULA FARMÁCIA DE MANIPULAÇÃO – MOEMA: Av. Ibirapuera, 1898 - SP - Tel: 5051-2601 - Fax: 5052-5114 - WhatsApp 11
Referências
14
Zocco MA1, dal Verme LZ, Cremonini F, Piscaglia AC, Nista EC, Candelli M, Novi M, Rigante D, Cazzato IA, Ojetti V, Armuzzi A, Gasbarrini G, Gasbarrini A. Efficacy of Lactobacillus GG in
atendimentomedico@biformula.com.br
maintaining remission of ulcerative colitis. Aliment Pharmacol Ther. 2006 Jun 1;23(11):1567-74. - www.biformula.com.br
Colite Ulcerativa
Bifidobacterium infantis Reduz Biomarcadores
Inflamatórios
Objetivo do Estudo
Um estudo conduzido por Groeger et al. (2013) teve como objetivo avaliar o impacto da
administração oral de Bifidobacterium infantis sobre biomarcadores inflamatórios e nos
níveis de citocinas no plasma em pacientes com colite ulcerativa.
Um total de 22 pacientes com colite ulcerativa foi selecionado para participar

deste estudo duplo-cego e controlado por placebo e randomizado para receber,
durante 6 a 8 semanas:
Grupo I
Grupo II
Bifidobacterium infantis
Placebo
1x109 UFC/dia
 A suplementação com B. infantis resultou na diminuição dos níveis plasmáticos

de proteína C-reativa (PCR) quando comparada com o placebo;
 Os níveis de interleucina-6 (IL-6) também foram reduzidos com a suplementação

de B. infantis.
Os resultados demonstraram a capacidade de B. infantis em

reduzir biomarcadores inflamatórios em pacientes com colite
ulcerativa.
Referências
Groeger D1, O'Mahony L, Murphy EF, Bourke JF, Dinan TG, Kiely B, Shanahan F, Quigley EM. Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut. Gut
Microbes. 2013 Jul-Aug;4(4):325-39. doi: 10.4161/gmic.25487. Epub 2013 Jun 21.
Idosos Submetidos à Cirurgia
Colorretal
Terapia Probiótica Pós-operatória Reduz
Complicações Associadas à Antibioticoterapia
O tratamento antibiótico profilático perioperatório influencia de maneira significativa a
microflora intestinal, resultando em alteração da função intestinal em alguns indivíduos
Isso pode afetar significativamente a qualidade de vida dos pacientes.
Objetivo do Estudo
Avaliar os efeitos de um pool de probióticos administrados no período pós-operatório

imediato em pacientes idosos submetidos à cirurgia colorretal (Pellino et al., 2013).
Pacientes idosos submetidos à cirurgia colorretal laparoscópica foram

selecionados para receber:
Grupo I Grupo II
Antibióticos (perioperatório) + Antibióticos (perioperatório) +
Probióticos* (pós-operatório) Placebo
*Os pacientes do grupo I receberam uma mistura diária de probióticos, dividida em 2

tomadas, iniciando 1 dia após a descontinuação da terapia antibiótica, sendo composta
por: 900 x 109 UFC de Streptococcus thermophilus, Bifidobacteria longum, Bifidobacteria
breve, Bifidobacteria infantis, Lactobacillus acidophilus, Lactobacillus plantarum,
Lactobacillus paracasei, Lactobacillus delbrueckii.
Resultados
 Os pacientes do grupo I apresentaram melhora do trânsito intestinal, com

melhora da consistência das fezes e consequente melhora da qualidade de
vida, em comparação com o grupo II.
Referências
Pellino G, Sciaudone G, Candilio G, Camerlingo A, Marcellinaro R, De Fatico S, Rocco F, Canonico S, Riegler G, Selvaggi F. Early postoperative administration of probiotics versus placebo
in elderly patients undergoing elective colorectal surgery: a double-blind randomized controlled trial. BMC Surg. 2013;13 Suppl 2:S57. doi: 10.1186/1471-2482-13-S2-S57. Epub 2013 Oct 8.
Infecção por H. pylori
Lactobacillus reuteri Reduz Efeitos Adversos
Associados à Terapia Antibiótica
Objetivo do Estudo
O objetivo desse estudo conduzido por Efrati et al. (2012) foi avaliar a terapia sequencial
e a suplementação com L. reuteri no tratamento para erradicação de H. pylori.
Noventa pacientes dispépticos, H. pylori positivos foram submetidos a 2

protocolos de tratamento:
Protocolo 2 - Duração 10 dias

Protocolo 1 - Duração 7 dias
Terapia sequencial (IBP + amoxicilina por 5 dias,
Terapia Tripla (IBP* + claritromicina + amoxicilina
seguido de IBP + claritromicina + tinidazol por mais
ou metronidazol) por 7 dias + Lactobacillus reuteri
5 dias) + Lactobacillus reuteri 1x108 UFC/dia
1x108 UFC/dia (durante o tratamento ou após sua
(durante o tratamento ou após sua finalização).
finalização).
*Inibidor de bomba protônica.
 A taxa de erradicação foi significativamente maior no grupo que recebeu a terapia

por 10 dias;
 Não foram observadas diferenças entre as taxas de erradicação nos pacientes
que receberam a suplementação com L. reuteri durante ou após a terapia tripla;
 As taxas de erradicação foram excelentes em todos os pacientes;
 Não foram observadas diferenças nos efeitos adversos entres os diferentes
antibióticos utilizados e também na forma de suplementação de L. reuteri;
 A baixa incidência de efeitos adversos em todos os grupos foi provavelmente
devido à presença do L. reuteri.
O tratamento de 10 dias alcançou uma taxa de erradicação mais elevada de H. pylori quando
comparado com o regime de 7 dias. A suplementação com L. reuteri reduziu a frequência e a
intensidade dos efeitos adversos associados ao regime com antibióticos.
Referências
Efrati C, Nicolini G, Cannaviello C, O'Sed NP, Valabrega S. Helicobacter pylori eradication: sequential therapy and Lactobacillus reuteri supplementation. World J Gastroenterol. 2012 Nov
21;18(43):6250-4. doi: 10.3748/wjg.v18.i43.6250.
Infecção por H. pylori
Associação Probiótica Aumenta a Eficácia da
Terapia Tripla, Reduzindo a Ocorrência de Efeitos
Adversos
Objetivo do Estudo
Hauser et al. (2015) conduziram um estudo para avaliar a eficácia da associação de

probióticos com a terapia padrão na erradicação da infecção por H. pylori.
Um total de 804 pacientes H. pylori positivos foi selecionado para receber 1 dos
seguintes protocolos abaixo por 14 dias:
Grupo I
Terapia tripla +
Grupo II
Cápsula de probióticos (Lactobacillus rhamnosus +
Terapia tripla + placebo
Bifidobacterium spp. - 108 a 1010
UFC) - 2 vezes ao dia
 Os resultados demonstraram que houve maior taxa de cura dos indivíduos no

grupo I em comparação com o grupo II;
 A terapia com probióticos promoveu melhora de sintomas, como dor epigástrica,
inchaço abdominal, flatulência, alterações de paladar, perda de apetite, náuseas,
vômitos, queimação, rash e diarreia;
 A intensidade de efeitos adversos associados à terapia antibiótica foi
significativamente superior no grupo placebo.
A adição de probióticos à terapia tripla padrão anti H. pylori contribui significativamente para
a eficácia do tratamento e reduz ainda a incidência de efeitos adversos associados à terapia,
reduzindo também sintomas assciados à doença.
Referências
Formulações
Hauser G1, Salkic N, Vukelic K, JajacKnez A, Stimac D. Probiotics for standard triple Helicobacter pylori eradication: a randomized, double-blind, placebo-controlled trial. Medicine
(Baltimore). 2015 May;94(17):e685. doi: 10.1097/MD.0000000000000685.
Formulário 1
Constipação / Diarreia / Cólica Infantil
Constipação Intestinal Crônica
Iogurte Simbiótico
Lactobacillus acidophilus.....1 x 109 UFC

Bifidobacterium bifidum........1 x 109 UFC
Polidextrose.....................................3,6 g
Base para Iogurte qsp................1 Sachê
Administrar 1 sachê ao dia ou conforme orientação

médica/nutricional.
Prevenção/Tratamento da Diarreia Associada à Antibioticoterapia
Cápsulas de Lactobacillus reuteri
Lactobacillus reuteri..............1 x 109 UFC

Excipiente qsp.........................1 Cápsula
Administrar 2 cápsulas ao dia ou conforme orientação

Tratamento da Diarreia Aguda em Crianças
Iogurte Enriquecido com Probióticos
Lactobacillus casei..............10 x 109 UFC


Tratamento da Cólica em Crianças
Cápsulas com L. reuteri
Lactobacillus reuteri..............1 x 108 UFC

Administrar 1 cápsula ao dia ou conforme orientação

Formulário 2
Alívio dos Sintomas e Melhora da Consistência das Fezes
Pool de Probióticos
Lactobacillus acidophilus.......3,5 x 109 UFC

Lactobacillus plantarum.........3,5 x 109 UFC
Lactobacillus rhamnosus.......3,5 x 109 UFC
Bifidobacterium breve............3,5 x 109 UFC
Bifidobacterium lactis.............3,5 x 109 UFC
Bifidobacterium longum.........3,5 x 109 UFC
Streptococcus termophilus....3,5 x 109 UFC
Excipiente qsp................................1 Sachê

Probióticos Isolados
Lactobacillus acidophilus
Ou na dose de 2,5 x 1010 UFC/dia
Lactobacillus acidophilus..........2 x 10 UFC 9
Dose diária ou conforme orientação médica/nutricional.
Lactobacillus plantarum
Lactobacillus plantarum............5 x 107 UFC
Lactobacillus reuteri............1 x 108 UFC
Administrar 2 vezes ao dia ou conforme orientação

Formulário 3
Doença de Crohn e Colite Ulcerativa
Doença de Crohn - Indução da Remissão
Altas Doses de Probióticos
Lactobacillus spp.............37,5 x 109 UFC

Bifidobacterium spp.........37,5 x 109 UFC
Prebiótico
Psyllium.............................................10 g
Excipiente qsp............................1 Sachê
Colite Ulcerativa - Manutenção da Remissão
Lactobacillus rhamnosus
Lactobacillus rhamnosus......9 x 109 UFC

Administrar 2 vezes ao dia ou conforme orientação

Colite Ulcerativa - Redução da Inflamação
Bifidobacterium infantis
Bifidobacterium infantis........1 x 109 UFC

Formulário 4
Terapia Probiótica Pós-operatória e Infecção por
H. pylori
Pacientes Submetidos à Cirurgia Colorretal - Prevenção de Complicações
Associada à Antibioticoterapia
Altas Doses de Probióticos Associados
Streptococcus termophilus.....112,5 x 109 UFC

Bifidobacterium longum..........112,5 x 109 UFC
Bifidobacterium breve.............112,5 x 109 UFC
Bifidobacterium infantis...........112,5 x 109 UFC
Lactobacillus acidophilus........112,5 x 109 UFC
Lactobacillus plantarum..........112,5 x 109 UFC
Lactobacillus paracasei..........112,5 x 109 UFC
Lactobacillus delbrueckii.........112,5 x 109 UFC
Dose diária ou conforme orientação médica.
Infecção por H. pylori - Redução dos Efeitos Adversos da Terapia Tripla
Cápsulas de L. reuteri
Lactobacillus reuteri.......................1 x 108 UFC

Excipiente qsp..................................1 Cápsula
Infecção por H. pylori - Aumento da Eficácia da Terapia Tripla
Associação Probiótica
Lactobacillus rhamnosus............5 x 108-10 UFC

Bifidobacterium spp...................5 x 108-10 UFC
Administrar 2 vezes ao dia ou conforme orientação médica.
Probióticos nas Doenças
Metabólicas
Hipercolesterolemia
Associação Probiótica Reduz o Colesterol Total
em 10,3%
Objetivo do Estudo
Rerksuppaphol e Rerksuppaphol (2015) conduziram um estudo para avaliar a eficácia

de uma associação probiótica (Lactobacillus + Bifidobacterium) sobre os parâmetros
lipídicos de pacientes hipercolesterolêmicos.
Um total de 64 indivíduos hipercolesterolêmicos foi selecionado, e dividido em

2 grupos para receber por 6 semanas:
Grupo I (n=31)
Grupo II (n=33)
Lactobacillus acidophilus (109 UFC)
Placebo
+
Bifidobacterium bifidum (109 UFC) - 3 vezes ao dia
Resultados
Probióticos Placebo
Diferença Diferença
Valor Médio Média (do valor Valor Médio Média (do valor
basal) basal)
Colesterol Total
Linha Base 237,2 231,0
Semana 6 212,7 -24,5 252,8 +21,8
LDL-c
Semana 6 153,9 -4,2 182,1 +22,6
Triglicerídeos
Semana 6 148,0 -28,0 145 -5,4
Referências
Rerksuppaphol S1, Rerksuppaphol L2. A Randomized Double-blind Controlled Trial of Lactobacillus acidophilus Plus Bifidobacterium bifidum versus Placebo in Patients with
Hypercholesterolemia. J Clin Diagn Res. 2015 Mar;9(3):KC01-4. doi: 10.7860/JCDR/2015/11867.5728. Epub 2015 Mar 1.
Hipercolesterolemia
Lactobacillus reuteri Reduz a Absorção de Esterol
Objetivo do Estudo
A porcentagem de pacientes hipercolesterolêmicos que não atingem os níveis alvo de

LDL-c permanece elevada, sendo necessária a avaliação de terapêuticas adicionais. O
objetivo de um estudo conduzido por Jones et al., (2012) foi avaliar os efeitos
hipolipidêmicos da suplementação com probióticos.
Cento e vinte sete indivíduos com hipercolesterolemia foram divididos para

receber, por 9 semanas: cápsulas com L. reuteri ou placebo por 9 semanas.
Cápsulas com L. reuteri ou placebo
Parâmetro Redução por L. reuteri

LDL-c 11,64%
Colesterol Total 9,14%
Colesterol Não HDL 11,3%
ApoB-100 8,41%
Razão LDL-c/HDL-c 13,39%
Razão ApoB-100/ApoA-1 9,00%
PCR de alta sensibilidade 1,05 mg/L
 Além disso, houve aumento de 1,00 nmol/L nos níveis de ácidos biliares
desconjugados.
O presente estudo sugere que a desconjugação de ácidos biliares resulta em redução da

absorção de esterol e indica que a suplementação com L. reuteri é eficaz como adjuvante no
tratamento da hipercolesterolemia
Referências
Jones ML1, Martoni CJ, Di Pietro E, Simon RR, Prakash S. Evaluation of clinical safety and tolerance of a Lactobacillus reuteri NCIMB 30242 supplement capsule: a randomized control trial.
Regul Toxicol Pharmacol. 2012 Jul;63(2):313-20. doi: 10.1016/j.yrtph.2012.04.003. Epub 2012 Apr 25.
Dislipidemia em Crianças
Pool Probiótico é Eficaz na Modulação do Perfil
Lipídico
Objetivo do Estudo
Guardamagna et al. (2014) conduziram um estudo que teve como objetivo avaliar os
efeitos da administração de um pool probiótico contendo 3 cepas de Bifidobacterium
sobre o perfil lipídico de crianças dislipidêmicas.
Trinta e oito crianças com dislipidemia, com idades entre 10,8 ± 2,1, foram
selecionadas e, após serem submetidas a uma dieta de 4 semanas, foram
divididas para receber por 3 meses:
Grupo I
Bifidobacterium lactis Grupo II
Bifidobacterium bifidum Placebo
Bifidobacterium longum
(1x109 UFC cada)
Resultados
Parâmetro Valor Inicial Após tratamento com

probióticos
Colesterol Total 222,8 ± 23,2 mg/dL 211,9 ± 27,3 mg/dL
HDL-c 55,8 ± 12,2 mg/dL 60,7 ± 14,2 mg/dL
Triglicerídeos 99,0 ± 61,7 mg/dL 79,5 ± 34,5 mg/dL
LDL-c 147,2 ± 21,9 mg/dL 135,3 ± 24,2 mg/dL
 Em comparação com a administração de placebo, os probióticos promoveram

redução do colesterol total em 3,4% e do LDL-c em 3,8%.
Referências
Guardamagna O1, Amaretti A2, Puddu PE3, Raimondi S2, Abello F4, Cagliero P4, Rossi M2. Bifidobacteria supplementation: effects on plasma lipid profiles in dyslipidemic children.
Nutrition. 2014 Jul-Aug;30(7-8):831-6. doi: 10.1016/j.nut.2014.01.014. Epub 2014 Feb 15.
Obesidade
Lactobacillus gasseri Reduz o Peso Corporal e a
Circunferência do Quadril e Cintura
Objetivo do Estudo
Jung et al. (2013) conduziram um estudo que teve como objetivo avaliar os efeitos da
suplementação com L. gasseri sobre parâmetros antropométricos em indivíduos obesos
e sobrepesados.
Um total de 62 indivíduos com IMC ≥ 23 kg/m2 e glicose de jejum ≥ 100 mg/dL

foi selecionado e dividido em 2 grupos para receber, por 12 semanas:
Grupo I
Lactobacillus gasseri Grupo II
1x1010 UFC Placebo
2 cápsulas, 3 vezes ao dia
Após 12 semanas de tratamento com Lactobacillus reuteri, foram observados:
 Redução significativa do peso corporal;

 Redução da circunferência do quadril e cintura, de maneira superior ao grupo
placebo;
 Tratamento livre de efeitos adversos.
Este estudo permitiu concluir que a suplementação com probióticos é uma estratégia
segura e eficaz para tratamento complementar na perda de peso.
Referências
Jung SP1, Lee KM, Kang JH, Yun SI, Park HO, Moon Y, Kim JY. Effect of Lactobacillus gasseri BNR17 on Overweight and Obese Adults: A Randomized, Double-Blind Clinical Trial. Korean J
Fam Med. 2013 Mar;34(2):80-9. doi: 10.4082/kjfm.2013.34.2.80. Epub 2013 Mar 20.
Obesidade
Lactobacillus rhamnosus Promove Redução do
Peso e da Massa Gorda em Mulheres Obesas
Objetivo do Estudo
Sanchez et al. (2014) conduziram um estudo que teve como objetivo avaliar os efeitos
da suplementação com L. rhamnosus sobre a perda de peso e sua manutenção em
homens e mulheres obesos.
Homens e mulheres saudáveis e sobrepesados foram incluídos nesse estudo

randomizado, com duração de 24 semanas, e que foi composto por 2 fases diferentes:
Fase 1 Fase 2
Fase de perda de peso – 12 semanas Manutenção do peso corporal – 12 semanas
Restrição dietética supervisionada com suplementação Supervisão dos hábitos alimentares sem restrição, com
de L. rhamnosus ou placebo continuação da suplementação com L. rhamnosus ou
placebo
Formulação Avaliada
Cápsulas de Lactobacillus rhamnosus
1,62 x 108 UFC + prebiótico
2 vezes ao dia
Resultados
 A média de perda de peso entre as mulheres que receberam L. rhamnosus foi

significativamente superior do que a média de perda de peso entre as mulheres
que receberam placebo (p=0,02) após 12 semanas;
 As mulheres do grupo L. rhamnosus continuaram a perder peso e massa gorda
durante a fase de manutenção do peso corporal;
 A perda de peso induzida pelo L. rhamnosus nas mulheres estava relacionada
com redução significativa da massa gorda, com redução dos níveis de leptina
circulante e também com uma abundância fecal das bactérias da família
Lachnospiraceae.
Referências
BIFÓRMULA
Sanchez M1, Darimont C2,FARMÁCIA
Drapeau V3, DE MANIPULAÇÃO
Emady-Azar S4, Lepage – MOEMA:
M5, RezzonicoAv.
E2, Ibirapuera,
Ngom-Bru C5,1898
Berger- B2,
SP -Philippe
Tel: 5051-2601 - Fax: C2,
L4, Ammon-Zuffrey 5052-5114
Leone P2, -Chevrier
WhatsApp 11
G6, St-Amand E6, 28
Marette A6, 97550-0995 - VILA
Doré J1, Tremblay MARIANA:
A1. Effect Av. Cons.
of Lactobacillus Rodrigues
rhamnosus Alves, 203
CGMCC1.3724 - SP - Tel: 5575-0765
supplementation on weight loss- Fax: 5575-4613in -obese
and maintenance WhatsApp
men and11 97510-4000
women. Br J Nutr. 2014 Apr
28;111(8):1507-19. doi: 10.1017/S0007114513003875. Epub 2013 Dec 3.
Doença Hepática Gordurosa
Não-acoólica
Pool de Probióticos Reduz Enzimas Hepáticas
Objetivo do Estudo
Os probióticos têm um profundo efeito sobre a doença hepática gordurosa não-

alcoólica (DHGNA) em modelos animais. O objetivo desse estudo conduzido por Wong
et al. (2013) foi avaliar os efeitos do tratamento com probióticos em pacientes com
DHGNA.
Um total de 20 pacientes com DHGNA foi selecionado para participar deste

estudo, e dividido em 2 grupos para receber
Grupo I (n=10)
Pool de Probióticos - 2x108 UFC
Lactobacillus plantarum Grupo II (n=10)
Lactobacillus delbrueckii Placebo
Lactobacillus acidophilus
Lactobacillus rhamnosus
Bifidobacterium bifidum
 A primeira medida de avaliação foi o IHTG – Intrahepatic Triglyceride Content, que mede o
conteúdo de lipídeos no interior dos hepatocitos;
 A segunda medida de avaliação foi o perfil bioquímico e metabólico dos pacientes.
Resultados
 O IHTG reduziu de 22,6 +/- 8,2% para 14,9 +/- 7,0% no grupo probiótico
(p=0,034), mas permaneceu inalterado no grupo controle (16,9 +/- 6,1% para
16,0 +/- 6,6% (p=0,55);
 O grupo probiótico também teve grande redução dos níveis séricos de aspartato
aminotransferase (AST);
 O uso de probióticos não foi associado com alterações no IMC, circunferência
da cintura e os níveis de glicose e lipídeos.
Referências
Wong VW1, Won GL, Chim AM, Chu WC, Yeung DK, Li KC, Chan HL. Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. Ann Hepatol. 2013 Mar-
29
Apr;12(2):256-62.
Formulações
Formulário 1
Hipercolesterolemia / Dislipidemia
Iogurte Redutor do Colesterol

Administrar 1 sachê, 3 vezes ao dia ou conforme

orientação médica.
Redução da Absorção de Gorduras
Cápsulas de L. reuteri
Lactobacillus reuteri.........2,9 x 109 UFC*

Administrar 1 cápsula, 2 vezes ao dia ou conforme

* De acordo com Jones et al. (2012), a administração de L. reuteri (2,9 x 109 UFC, 2 vezes ao dia) se
mostrou segura e bem tolerada em indivíduos adultos por um período de 9 semanas.
Modulação do Perfil Lipídico em Crianças Dislipidêmicas
Bifidobacterium lactis............1 x 109 UFC

Bifidobacterium longum........1 x 109 UFC

médica.
Referências
Jones ML1, Martoni CJ, Prakash S. Cholesterol lowering and inhibition of sterol absorption by Lactobacillus reuteri NCIMB 30242: a randomized controlled trial. Eur
30
J Clin Nutr. 2012
Nov;66(11):1234-41. doi: 10.1038/ejcn.2012.126. Epub 2012 Sep 19.
Formulário 2
Obesidade / DHGNA
Redução do Peso Corporal e da Circunferência da Cintura
Cápsulas de Lactobacillus gasseri
Lactobacillus gasseri...........1 x 1010 UFC

Administrar 2 cápsulas, 3 vezes ao dia ou conforme

Redução do Peso e da Massa Gorda em Mulheres
Cápsulas de Lactobacillus rhamnosus
Lactobacillus rhamnosus........1,62 x 108 UFC

FOS qsp.........................................1 Cápsula

Redução de Enzimas Hepáticas na DHGNA
Lactobacillus plantarum...............4 x 107 UFC

Lactobacillus delbrueckii.............4 x 107 UFC
Lactobacillus acidophilus............4 x 107 UFC
Lactobacillus rhamnosus.............4 x 107 UFC
Bifidobacterium bifidum...............4 x 107 UFC
FOS...........................................................4 g
Excipiente qsp...................................1 Sachê

médica.
Probióticos e Tratamento de
Condições Cutâneas
Tratamento da Acne
Probióticos Promovem Melhora Clínica da Acne e
Aumentam a Tolerabilidade ao Tratamento Padrão
Estudo 1 - Probióticos Orais Promovem Melhora Clínica em 80% dos Pacientes com
Acne
A primeira evidência sobre o benefício do uso dos probióticos na acne foi publicada em
1961, abordando o potencial dos Lactobacillus nesta condição. Para a realização deste
estudo, 300 pacientes foram tratados com:
Mistura de L. acidophilus e L. bulgaricus

Por via oral durante 8 dias, seguidos por duas semanas de wash-out e
reintrodução de probióticos por um período adicional de oito dias.
 Os resultados mostraram que 80% das pessoas com acne apresentaram algum
grau de melhoria clínica e que a intervenção foi mais efetiva em casos de acne
inflamatória.
Estudo 2 - Probióticos Aumentam Eficácia e Tolerabilidade ao Tratamento Padrão da

Acne
Um estudo conduzido por Marchetti et al. (1987) teve como objetivo avaliar os efeitos da
regulação da microbiota intestinal com probióticos sobre a terapia da acne vulgar.
Quarenta pacientes acometidos pela acne foram divididos em 2 grupos:
Grupo 2
Grupo 1 Tratamento padrão + Suplemento oral
Tratamento padrão adjuvante com L. acidophilus e B.
bifidum
 Além de melhores resultados clínicos entre os pacientes suplementados com os

probióticos, os pesquisadores relataram melhor adesão terapêutica e aumento
da tolerabilidade ao tratamento com antibióticos.
Referências
Siver RH: Lactobacillus for the control of acne. J Med Soc New Jersey 1961,59:52-53.
Marchetti F, Capizzi R, Tulli A: Efficacy of regulators of the intestinal bacterial flora in the therapy of acne vulgaris. Clin Ter 1987, 122:339-43, Italian.
33
Tratamento da Acne
Pool de Probióticos Apresenta Efeito Sinérgico
com Antibióticos no Tratamento da Acne
Objetivo do Estudo
Jung et al.(2013) conduziram um estudo para avaliar se a adminsitração de probióticos

seria capaz de reduzir os efeitos adversos sistêmicos causados pelos antibióticos
enquanto age sinergicamente com este para o tratamento da acne inflamatória.
Neste estudo prospectivo e aberto, 45 mulheres, com idades entre 18 e 35

anos, foram randomizadas em 3 grupos:
Grupo I Grupo III

L. acidophilus 5 x 109 UFC; Grupo II Minociclina +
L. delbrueckii 5 x 109 UFC; Minociclina Suplementação de probióticos, no
B. bifidum 20 x 109 UFC, mínimo 2 horas após a dose de
2 vezes ao dia. minociclina.
Todos os pacientes receberam tratamento tópico com peróxido de benzoíla e uma formulação de limpeza facial, aplicados 2
vezes ao dia, uma pela manhã e outra à noite. Não foi permitido o uso adicional de nenhum outro tratamento antiacne.
 Todos os pacientes apresentaram uma melhora significativa na contagem total

de lesões após 4 semanas de tratamento (p<0,001), com melhora contínua
reportada a cada visita subsequente (p<0,01);
 Ao final de 8 e 12 semanas de visitas, o grupo 3 apresentou uma redução
significativa na contagem total das lesões acneicas versus o grupo 1 (p<0,001)
e B (p<0,01);
 Dois pacientes (13%) do grupo 2 não completaram o estudo.
Os probióticos podem ser considerados uma opção terapêutica ou adjuvante no

tratameno da acne vulgar por fornecer um efeito anti-inflamatório sinérgico com
antibióticos sistêmicos enquanto também reduz os potenciais efeitos adversos
secundários ao uso crônico de antibióticos.
Referências
Jung GW1, Tse JE, Guiha I, Rao J. Prospective, randomized, open-label trial comparing the safety, efficacy, and tolerability of an acne treatment regimen with and without a probiotic
supplement and minocycline in subjects with mild to moderate acne. J Cutan Med Surg. 2013 Mar-Apr;17(2):114-22.
Dermatite Atópica
Lactobacillus salivarius Modula o Status
Imunológico na Dermatite Atópica Moderada a
Severa
Objetivo do Estudo
Drago et al. (2012) conduziram um estudo que teve como objetivo avaliar os efeitos
imunomodulatórios da suplementação com probióticos e sua capacidade de interferir
sobre o escore de severidade da dermatite atópica em adultos.
Trinta e oito pacientes com idades entre 18 e 46 anos com DA moderada a

severa foram incluídos nesse estudo e divididos em 2 grupos para receber:
Grupo I (n=19) Grupo II (n=19)

Suplementação com L. salivarius Placebo
 Lactobacillus salivarius demonstrou exercer efeitos imunomoduladores;

 Após suplementação, foi observada redução do SCORAD (índice que avalia a
severidade da dermatite atópica);
 Lactobacillus salivarius também foi capaz de reduzir a produção de citocinas por
Th2, mantendo a produção de citocinas por Th1 estável.
Esses resultados comprovam os efeitos imunomoduladores de probióticos específicos,

reforçando seus benefícios na modificação clínica de doenças como a dermatite
atópica, levando ao reequilíbrio da microbiota intestinal alterada.
Referências
Drago L1, Toscano M, De Vecchi E, Piconi S, Iemoli E. Changing of fecal flora and clinical effect of L. salivarius LS01 in adults with atopic dermatitis. J Clin Gastroenterol. 2012 Oct;46
Suppl:S56-63. doi: 10.1097/MCG.0b013e318265ef38.
Dermatite Atópica Infantil
Pool de Probióticos Reduz a Inflamação e a
Severidade da Dermatite Atópica
Objetivo do Estudo
O objetivo deste estudo conduzido por Yeşilova et al. (2014) foi avaliar a eficácia
terapêutica de um pool de probióticos em crianças com dermatite atópica leve a
moderada.
Participaram deste estudo clínico duplo-cego, randomizado e placebo-

controlado 40 crianças com dermatite atópica (1 a 13 anos de idade). Elas
foram randomizadas para receber a seguinte posologia por 8 semanas:
Grupo I
Lactobacillus casei - 2x109UFC
Lactobacillus rhamnosus - 2x109UFC Grupo II
Lactobacillus plantarum - 2x109UFC Placebo
Bifidobacterium bifidum - 2x109UFC
2 vezes ao dia
Nos grupos 1 e 2 foram medidos os níveis séricos de citocinas plasmáticas, os níveis de imunoglobulina E (IgE)
e o SCORing Atopic Dermatitis (SCORAD) index.
A intervenção com um pool de probiótiocos em pacientes com dermatite atópica

reduziu o SCORAD e os níveis séricos das interleucinas IL-5, IL-6, interferon (IFN)-γ e os
níveis séricos de IgE, mas não reduziu os níveis das interleucinas IL-2, IL-4, IL-10 e fator
de necrose tumoral alfa (TNF-α) quando comparada com o grupo placebo.
De acordo com os resultados, o pool de probióticos foi efetivo na redução dos escores
que medem a atividade da doença (SCORAD) e nos níveis séricos das interleucinas IL-
5, IL-6, interferon (IFN)-γ e os níveis séricos de IgE.
Referências
Yeşilova Y, Çalka Ö, Akdeniz N, Berktaş M. Effect of probiotics on the treatment of children with atopic dermatitis. Ann Dermatol. 2012 May;24(2):189-93. doi: 10.5021/ad.2012.24.2.189.
Epub 2012 Apr 26.
Dermatite Atópica Infantil
Bifidobacterium bifidum é Eficaz na Prevenção e
Tratamento
Objetivo do Estudo
Fornecer evidência para a aplicação de probióticos na prevenção e tratamento do

eczema atópico infantil, através das alterações nos níveis de bifidobactérias intestinais e
nos escores de dermatite atópica (SCORAD) antes e após o tratamento com probióticos
em crianças com eczema (Lin et al., 2015).
Um total de 40 crianças com eczema foi dividido aleatoriamente em grupos de

tratamento e controle:
Grupo I (n=20)
Grupo II (n=20)
1 cápsula de B. bifidum
Sem tratamento
3 vezes ao dia por 4 semanas
 Após quatro semanas de tratamento com B. bifidum, os níveis intestinais de B.

bifidum aumentaram acentuadamente (p<0,05) e o índice SCORAD foi
notavelmente reduzido (p<0,05) em comparação com os valores basais;
 Em contraste, nem o teor de B. bifidum nem o índice SCORAD tiveram alterações
significativas no grupo controle após quatro semanas (p>0,05);
 Após o tratamento, os níveis de B. bifidum nas fezes do grupo de tratamento
foram significativamente mais elevados (p<0,05) e o índice SCORAD foi
significativamente menor (p<0,05) quando comparados com o controle.
A suplementação de probióticos possui um efeito positivo sobre a prevenção e o

tratamento de eczema atópico infantil.
Referências
Lin RJ, Qiu LH, Guan RZ, Hu SJ, Liu YY, Wang GJ. Protective effect of probiotics in the treatment of infantile eczema. ExpTher Med. 2015 May;9(5):1593-1596. Epub 2015 Feb 17.
Fotoproteção
L. johnsonii Preserva a Homeostase Cutânea Após
a Exposição à Radiação UV
Objetivo do Estudo
Estudo clínico randomizado, duplo-cego e placebo-controlado conduzido por Guéniche

et al. (2009) teve como objetivo avaliar os efeitos da suplementação com L. johnsonii
sobre a homeostase cutânea após exposição à radiação ultravioleta.
Cinquenta e quatro voluntários foram randomizados em dois grupos para

receberem por oito semanas, antes da exposição à radiação ultravioleta, a
seguinte posologia:
Grupo I
Lactobacillus johnsonii Grupo II
1x1010 UFC Placebo
Dose diária
 A suplementação com probióticos promoveu significativa regulação do sistema

imune intestinal promovendo um equilíbrio do sistema imune cutâneo,
demonstrado através da modulação das células linfocitárias epidermais mistas
(MECLR), o que é importante para a fotoproteção cutânea;
 Houve também um aumento dos níveis de IgA no inestino delgado, junto com
um maior número de células dendríticas na pele.
Os resultados do estudo fortalecem a hipótese de que certos probióticos podem

contribuir para modular o sistema imunológico cutâneo preservando a sua
homeostase. Dessa maneira os probióticos podem ser utilizados para tratar e prevenir
os efeitos cutâneos oriundos da exposição à radiação UV.
Referências
Guéniche A, Philippe D, Bastien P, Blum S, Buyukpamukcu E, Castiel-Higounenc I. Probiotics for photoprotection. Dermatoendocrinol. 2009 Sep;1(5):275-9.
Fotoenvelhecimento
Lactobacillus plantarum Apresenta Ação Anti-
ageing
Objetivo do Estudo
Já foi observado que o probiótico L. plantarum apresenta efeitos hidratantes, além de

propriedades antifotoenvelhecimento.
Lee et al. (2015) conduziram um estudo que teve como objetivo avaliar a eficácia anti-
ageing de probióticos, especificamente, L. plantarum.
Nesse estudo, 110 voluntários com idades entre 41 e 59 anos com pele
ressecada e rugas foram divididos para receber por 12 semanas:
Grupo I
Lactobacillus plantarum Grupo II (n=27)
1x1010 UFC Placebo
Dose diária
 O grupo que recebeu probióticos apresentou aumento significativo da hidratação

da pele da face e das mãos após 12 semanas;
 Houve redução significativamente superior da perda de água transepidermal no
grupo I em comparação com o grupo II;
 O grupo II também apresentou redução da profundidade de rugas e aumento do
brilho da pele;
 No grupo I, a elasticidade da pele foi aumentada em 13,17% após 4 semanas e
em 21,73% após 12 semanas.
Esses resultados fornecem evidências sobre as propriedades anti-ageing dos

probióticos, sendo capazes de melhorar a aparência da pele fotoenvelhecida.
Referências
Lee DE1, Huh CS2, Ra J1, Choi ID1, Jeong JW1, Kim SH1, Ryu JH3, Seo YK3, Koh JS3, Lee JH1, Sim JH1, Ahn YT1. Clinical evidence of effects of Lactobacillus plantarum HY7714 on skin
aging: a randomized, double blind, placebo-controlled study. J Microbiol Biotechnol. 2015 Oct 2. doi: 10.4014/jmb.1509.09021. [Epub ahead of print]
Peles Reativas
Lactobacillus paracasei Melhora as Condições da
Pele Reativa
Nas últimas décadas, a prevalência de indivíduos com pele reativa tem aumentado
consideravelmente em países industrializados, sendo que cerca de 50% das mulheres e
30% dos homens já reportaram desconforto cutâneo, podendo ser classificado como
ocorrência de pele reativa/sensível.
Diversas abordagens tópicas têm sido sugeridas, particularmente através da melhora de

formas galênicas ou proteção da superfície epidérmica. No entanto, autores propuseram
um novo mecanismo de proteção da pele, atuando de dentro para fora, através de uma
abordagem nutricional, com o uso de probióticos.
Objetivo do Estudo
Gueniche et al. (2014) conduziram um estudo que teve como objetivo avaliar os efeitos
da suplementação com probióticos, especificamente Lactobacillus paracasei, sobre a
reatividade da pele em indivíduos com pele sensível. L. paracasei foi selecionado devido
a seus benefícios específicos para a pele, descobertos através de estudos in vitro, tais
como:
1. Redução da inflamação neurogênica;

2. Promoção da recuperação da função barreira cutânea.
Sessenta e quatro mulheres foram selecionadas para este estudo e divididas em

2 grupos para receber por 2 meses:
Grupo I (n=32) Grupo II (n=32)

Lactobacillus paracasei Placebo
Resultados
 Os resultados do estudo indicaram que a suplementação com L. paracasei

reduziu a sensibilidade da pele, além de aumentar a taxa de recuperação da
barreira cutânea, comprovando que esta pode ser uma nova estratégia para
redução da reatividade de peles sensíveis.
Referências
Gueniche A1, Philippe D2, Bastien P1, Reuteler G2, Blum S2, Castiel-Higounenc I1, Breton L1, Benyacoub J2. Randomised double-blind placebo-controlled study of the effect of
Lactobacillus paracasei NCC 2461 on skin reactivity. Benef Microbes. 2014 Jun 1;5(2):137-45. doi: 10.3920/BM2013.0001.
Formulações
Formulário 1
Tratamento da Acne
Associação Probiótica para Melhora Clínica da Acne
Lactobacillus acidophilus....1 x 109 UFC*

Lactobacillus bulgaricus.....1 x 109 UFC*

médica.
*Dose usual
Associação Probiótica para Aumento da Tolerabilidade ao Tratamento

Padrão
L. acidophilus + B. bifidum
Lactobacillus acidophilus....1 x 109 UFC*

Bifidobacterium bifidum......1 x 109 UFC*

médica.
*Dose usual
Pool Probiótico para Aumento da Eficác ia de Antibióticos

Lactobacillus delbrueckii.......5 x 109 UFC
Bifidobacterium bifidum.....20 x 1010 UFC

Formulário 2
Dermatite Atópica em Adultos e Crianças
Modulação do Status Imunológico na Dermatite Atópica
Cápsulas de L. salivarius
Lactobacillus salivarius........1 x 109 UFC*


médica.
*Dose usual.
Redução da Inflamação e da Severidade da Dermatite Atópica Infantil
Lactobacillus casei...............2 x 109 UFC

Lactobacillus rhamnosus......2 x 109 UFC
Lactobacillus plantarum........2 x 109 UFC
Excipiente qsp............................1 Sachê
Administrar 1 sachê, 2 vezes ao dia ou conforme

Prevenção da Dermatite Atópica Infantil
Cápsulas de B. bifidum
Bifidobacterium bifidum......1 x 109 UFC*


* Dose usual.
Formulário 3
Fotoproteção / Anti-ageing / Peles Reativas
Fotoproteção
Cápsulas de L. johnsonii
Lactobacillus johnsonii.........1 x 1010 UFC


médica.
Ação Anti-ageing e Antifotoenvelhecimento
Cápsulas de L. plantarum
Lactobacillus plantarum.......1 x 1010 UFC


médica.
Redução da Sensibilidade em Peles Reativas
Cápsulas de L. paracasei
Lactobacillus paracasei......1 x 109 UFC*


médica.
*Dose usual.
Probióticos e Doenças
Osteoarticulares
Osteoporose
Lactobacillus helveticus Aumenta a Densidade
Mineral Óssea em Pós-menopausadas
Objetivo do Estudo
Um estudo de revisão conduzido por Parvaneh et al. (2014) avaliou os efeitos da

suplementação de probióticos e seu papel na prevenção da perda mineral óssea. Os
resultados positivos dos probióticos foram apoiados pelo alto teor de cálcio na dieta e
pelas quantidades elevadas de probióticos suplementados.
Vinte mulheres pós-menopausadas com uma média de idade de 65 anos foram

divididas em 2 grupos para receber:
Grupo I Grupo II
Leite fermentado contendo Leite sem probióticos
Lactobacillus helveticus + +
Cálcio 600 mg/dia Cálcio 600 mg/dia
 A suplemetação do grupo I reduziu os níveis séricos de PTH (405,3 +/- 37 ng/l

vs. 454,9 +/- 37; p = 0,012) e aumentou os níveis séricos de cálcio (19,1 +/-
0,2 mmol/l vs. 18,8 +/- 0,2; p = 0,031) quando comparada com o placebo.
Os probióticos apresentaram potenciais efeitos sobre o metabolismo ósseo, através de

diferentes mecanismos.
Os resultados também mostraram que as mulheres na pós-menopausa com baixa

densidade da massa óssea são grupos potenciais para a suplementação de probióticos
para aumento da biodisponibilidade de minerais, incluindo cálcio e,
consequentemente, aumento da DMO (Narva et al., 2004).
Referências 45
Parvaneh K,97550-0995
Jamaluddin R, Karimi
- VILAG,MARIANA:
ErfaniR.Effectofprobioticssupplementationonbone
Av. Cons. Rodrigues Alves, 203 mineral
- SPcontentandbonemassdensity.
- Tel: 5575-0765 - Fax:ScientificWorldJournal.
5575-4613 - WhatsApp 2014 Jan11
22;2014:595962.
97510-4000
Narva M, Nevala R, Poussa T, KorpelaR.Theeffectof Lactobacillus helveticusfermentedmilkonacutechanges in calciummetabolism in postmenopausalwomen.Eur J Nutr. 2004 Apr;43(2):61-
8. Epub 2004 Jan 6.
Artrite Reumatoide
Lactobacillus casei Reduz a Inflamação na AR
Objetivo do Estudo
Como os probióticos são micro-organismos capazes de restabelecer o equilíbrio da

microbiota intestinal, que muitas vezes pode estar alterado na artrite reumatoide (AR),
Vaghef-Mehrabany et al. (2014) conduziram um estudo com o objetivo de avaliar os
efeitos da suplementação com probióticos sobre a atividade da doença e sobre a
liberação de citocinas inflamatórias em pacientes com AR.
Quarenta e seis pacientes com AR participaram deste estudo randomizado,

duplo-cego e placebo controlado, e foram divididos em 2 grupos, para receber
por 8 semanas:
Grupo I
Grupo II
Lactobacillus casei
Placebo
1 x 108 UFC/dia
 A suplementação com probióticos promoveu redução significativa da atividade

da doença, sendo que houve uma diferença estatística entre os dois grupos;
 No grupo 1, houve redução dos níveis de TNF-α, IL-6 e IL-12, comprovando a
ação dos probióticos sobre o status inflamatório dos pacientes;
 Os níveis de IL-1β não sofreram modificações;
 O grupo 1 também apresentou aumento dos níveis séricos de IL-10 (interleucina
reguladora);
 Além disso, houve aumento significativo da proporção entre IL-10 e IL-12 no
grupo que recebeu probióticos.
A suplementação com L. casei promoveu redução da atividade da AR e do status

inflamatório nesses pacientes, comprovando seu potencial como terapia adjunta na
artrite reumatoide
Referências
Vaghef-Mehrabany E1, Alipour B2, Homayouni-Rad A3, Sharif SK4, Asghari-Jafarabadi M5, Zavvari S6. Probiotic supplementation improves inflammatory status in patients with rheumatoid
BIFÓRMULA
arthritis. Nutrition. FARMÁCIAdoi:
2014 Apr;30(4):430-5. DE10.1016/j.nut.2013.09.007.
MANIPULAÇÃO – MOEMA: Epub 2013Av.
DecIbirapuera,
17. 1898 - SP - Tel: 5051-2601 - Fax: 5052-5114 - WhatsApp 11 46
Artrite Reumatoide
Lactobacillus casei Aumenta a Resposta ao
Tratamento em Mulheres
Objetivo do Estudo
Alipour et al. (2014) conduziram um estudo para avaliar os efeitos da suplementação

com L. casei sobre os sintomas e os marcadores inflamatórios em mulheres com AR.
Estudo randomizado, duplo-cego contou com 46 mulheres com histórico de AR

por, pelo menos, 1 ano e que usavam medicação estável por, no mínimo, 3
meses, foram divididas em 2 grupos para receber por 8 semanas:
Grupo I (n=22)
Grupo II (n=24)
Lactobacillus casei
Placebo
1 x 108 UFC/dia
 A suplementação com L. casei reduziu os níveis de PCR (proteína C reativa);

 O grupo 1 apresentou redução do número de articulações inchadas e dolorosas;
 Mais pacientes do grupo 1 apresentam resposta ao tratamento;
 Ao final do estudo, foram observadas diferenças significativas entre os níveis de
L-10, IL-12 e TNF-α dos pacientes de ambos os grupos, com resultados
melhores para o grupo 1;
 Não foram reportados efeitos adversos.
De acordo com o resultados, foi possível concluir que a suplementação com

probióticos pode ser uma estratégia apropriada como terapia adjuvante na AR,
auxiliando na redução da resposta inflamatória e dos sintomas.
Referências
Alipour B1, Homayouni-Rad A, Vaghef-Mehrabany E, Sharif SK, Vaghef-Mehrabany L, Asghari-Jafarabadi M, Nakhjavani MR, Mohtadi-Nia J. Effects of Lactobacillus casei supplementation
on disease activity and inflammatory cytokines in rheumatoid arthritis patients: a randomized double-blind clinical trial. Int J Rheum Dis. 2014 Jun;17(5):519-27. doi: 10.1111/1756-
185X.12333. Epub 2014 Mar 27.
Formulações
Formulário 1
Osteoporose e Artrite Reumatoide
Aumento da Densidade Mineral Óssea em Pós -menopausadas
Iogurte com Probióticos + Cálcio
Lactobacillus helveticus......1 x 109 UFC*

Cálcio Citrato Malato...................600 mg

médica.
*Dose usual
Redução da Inflamação e Aumento da Resposta ao Tratamento da Artrite

Reumatoide
Cápsulas de L. casei


médica.
Probióticos e Doenças
Alérgicas
Rinite Alérgica Persistente
Lactobacillus paracasei Aumenta a Eficácia de
Anti-histamínicos
Objetivo do Estudo
Estudos sugerem que o desequilíbrio entre as células Th1 e Th2 presente em quadros
de rinite alérgica pode ser melhorado após suplementação de probióticos. Por isso,
Costa et al. (2014) conduziram um estudo que teve como objetivo avaliar os efeitos da
administração de probióticos orais sobre a qualidade de vida de indivíduos com rinite
alérgica tratados com loratadina.
Um total de 425 indivíduos com rinite alérgica persistente recebeu loratadina

por 5 semanas e foi dividido em 2 grupos para receber por 5 semanas:
Grupo I Grupo II
Lactobacillus paracasei Placebo
 Após análise dos resultados, observou-se que houve redução significativa do

escore global RQLQ (Rhinitis Quality of Life) no grupo I em comparação com
grupo II;
 Não foram observadas alterações significativas com relação aos sintomas

nasais, no entanto, o grupo I apresentou melhora dos sintomas oculares superior
à apresentada pelo grupo II.
Esse estudo permitiu concluir que a administração de probióticos é uma estratégia

eficaz para controle dos sintomas da rinite alérgica persistente, aumentando a eficácia
de anti-histamínicos, além de melhorar a qualidade de vida dos pacientes.
Referências
Costa DJ1, Marteau P2, Amouyal M1, Poulsen LK3, Hamelmann E4, Cazaubiel M5, Housez B5, Leuillet S5, Stavnsbjerg M6, Molimard P7, Courau S7, Bousquet J8. Efficacy and safety of the
probiotic Lactobacillus paracasei LP-33 in allergic rhinitis: a double-blind, randomized, placebo-controlled trial (GA2LEN Study). Eur J Clin Nutr. 2014 May;68(5):602-7. doi:
10.1038/ejcn.2014.13. Epub 2014 Feb 26.
Rinite Alérgica Sazonal
Bifidobacterium lactis Modula Parâmetros
Imunológicos
Objetivo do Estudo
Singh et al. (2013) conduziram um estudo que teve como objetivo avaliar os efeitos da
administração oral de probióticos sobre parâmetros imunológicos e sintomas nasais em
indivíduos com rinite alérgica sazonal.
Indivíduos adultos com rinite alérgica sazonal foram selecionados para este
estudo e divididos em 2 grupos para receber por 8 semanas:
Grupo I Grupo II
Bifidobacterium lactis Placebo
 Após análise dos resultados, foi vericado que houve redução das concentrações
de citocinas de Th2, secretadas por linfócitos estimulados, superior no grupo I
quando comparado com o grupo II;
 O grupo I também apresentou redução dos sintomas nasais após 5 a 8
semanas;
 Outro resultado observado foi a redução da porcentagem de basófilos ativados
no grupo probióticos.
A administração de probióticos se mostrou uma estratégia eficaz para modulação de

parâmetros imunológicos em indivíduos com rinite alérgica sazonal, promovendo
melhora também de sintomas nasais.
Referências
Singh A1, Hacini-Rachinel F, Gosoniu ML, Bourdeau T, Holvoet S, Doucet-Ladeveze R, Beaumont M, Mercenier A, Nutten S. Immune-modulatory effect of probiotic Bifidobacterium lactis
NCC2818 in individuals suffering from seasonal allergic rhinitis to grass pollen: an exploratory, randomized, placebo-controlled clinical trial. Eur J Clin Nutr. 2013 Feb;67(2):161-7. doi:
10.1038/ejcn.2012.197. Epub 2013 Jan 9.
Alergia em Pacientes Rinopáticos
Iogurte Probiótico Reduz a Recorrência de Alergias
Associadas à Rinopatia
Objetivo do Estudo
Aldinucci et al. (2002) conduziram um estudo que teve como objetivo avaliar os efeitos
da administração de um iogurte enriquecido com probióticos sobre parâmetros clínicos
e imunológicos de pacientes rinopáticos com alergias frequentes.
Treze indivíduos com rinopatia foram selecionados para este estudo e divididos
em 2 grupos para receber por 4 meses:
Grupo I
Iogurte contendo:
Streptococcus thermophilus - 2 x 109 UFC Grupo II
Lactobacillus bulgaricus - 2 x 107 UFC Placebo
Lactobacillus acidophilus - 2 x 107 UFC
Bifidobacterium spp - 2 x 107 UFC
A suplementação de um iogurte enriquecido com probióticos se mostrou

eficaz na redução da recorrência e na melhora de alergias em pacientes
com rinopatia.
Referências
Aldinucci C1, Bellussi L, Monciatti G, Passàli GC, Salerni L, Passàli D, Bocci V. Effects of dietary yoghurt on immunological and clinical parameters of rhinopathic patients. Eur J Clin Nutr.
2002 Dec;56(12):1155-61.
Asma / Rinite Alérgia em Crianças
Lactobacillus gasseri Reduz Sinais Clínicos
Objetivo do Estudo
Estudo conduzido por Chen et al. (2010) teve como objetivo avaliar se a suplementação
com Lactobacillus gasseri promove melhoras nos sintomas clínicos e
imunomodulatórios em crianças com asma e rinite alérgica.
Cento e cinco crianças com idades entre 6 e 12 anos diagnosticadas com asma e
rinite alérgica foram randomizadas para receber, por 8 semanas, a seguinte
posologia:
Grupo I (n=49)
Grupo II (n=56)
Lactobacillus gasseri 2 x 109 UFC
Placebo
2 vezes ao dia
 A função pulmonar e o pico de fluxo expiratório (PFE) aumentaram de maneira

significativa e os escores que medem os sintomas clínicos da asma e da rinite
alérgica reduziram no grupo 1;
 Houve também maior redução da severidade dos sintomas da rinite alérgica no

grupo probióticos;
 Outro resultado observado no grupo 1 foi redução nos níveis de interleucinas

TNF-α, IFN-y, IL-12 e IL-13.
A suplementação com L. gasseri podem fornecer benefícios clínicos em crianças

sofrendo de processos alérgicos, como asma e rinite.
Referências
Chen YS1, Jan RL, Lin YL, Chen HH, Wang JY. Randomized placebo-controlled trial of lactobacillus on asthmatic children with allergic rhinitis. Pediatr Pulmonol. 2010 Nov;45(11):1111-20.
doi: 10.1002/ppul.21296.
Asma / Rinite Alérgica em Crianças
Lactobacillus casei Modula a Resposta Imune
Objetivo do Estudo
Giovannini et al. (2007) conduziram um estudo que teve como objetivo avaliar os efeitos
do consumo de um leite fermentado enriquecido com probióticos sobre os sintomas da
rinite alérgica/asma em crianças em idade pré-escolar.
Um total de 187 crianças com idades entre 2 e 5 anos foram selecionadas, e

divididas em 2 grupos para receber por 12 meses:
Grupo I
Grupo II
Leite fermentado contendo
Placebo
Lactobacillus casei (1 x 108 UFC)
 A redução dos episódios de crise de rinite foi maior após seis meses da ingestão
do leite fermentado enriquecido com probióticos;
 Os sintomas abdominais nas crianças com rinite também tiveram melhora com a
ingestão do produto contendo o probiótico, com menor duração dos episódios
de diarreia, comparados aos do grupo controle.
O consumo a longo prazo L. casei pode melhorar a qualidade de vida das

crianças com rinite alérgica.
Referências
Giovannini M1, Agostoni C, Riva E, Salvini F, Ruscitto A, Zuccotti GV, Radaelli G; Felicita Study Group. A randomized prospective double blind controlled trial on effects of long-term
consumption of fermented milk containing Lactobacillus casei in pre-school children with allergic asthma and/or rhinitis. Pediatr Res. 2007 Aug;62(2):215-20.
Alergia ao Leite em Crianças
Associação Probiótica Reduz Manifestações
Clínicas
Objetivo do Estudo
Ivakhnenko et al. (2013) conduziram um estudo que teve como objetivo avaliar os efeitos
da suplementação com probióticos sobre os sintomas gastrointestinais da alergia ao
leite de vaca em crianças.
Sessenta crianças com idades entre 3 e 12 meses com diagnóstico de dermatite

atópica e alergia ao leite de vaca foram divididas em 2 grupos para receber por
4 semanas:
Grupo I
Grupo II
Bifidobacterium lactis - 1 x 109 UFC
Placebo
Streptococcus thermophilus - 1 x 108 UFC
Resultados
 As crianças que receberam probióticos apresentaram redução significativa da

frequência de constipação intestinal, sendo esta ausente em 85,71% das
crianças do grupo I e em 48,15% do grupo II após 4 semanas e de 92,86% e
62,96% nos grupos I e II, respectivamente, após 8 semanas;
 O grupo I também apresentou redução da incidência de cólicas e diarreia.
A suplementação probiótica, associada a modificações dietéticas, representa uma boa

alternativa para redução dos sintomas gastrointestinais em crianças com alergia às
proteínas do leite de vaca.
Referências
Ivakhnenko ES, Nian'kovskiĭ SL. [Effect of probiotics on the dynamics of gastrointestinal symptoms of food allergy to cow's milk protein in infants]. Georgian Med News. 2013 Jun;(219):46-
52.
Suplementação Pré-Natal
Associação Probiótica Previne o Desenvolvimento
de Alergias em Bebês
Objetivo do Estudo
Enomoto et al. (2014) conduziram um estudo que teve como objetivo avaliar os efeitos
da suplementação pré-natal de probióticos sobre o desenvolvimento de alergias após o
nascimento das crianças.
Nesse estudo, 130 gestantes foram divididas em 2 grupos para receber por,
pelo menos, 7 meses:
Grupo I
Bifidobacterium breve Grupo II
Bifidobacterium longum Controle
5 x 109 UFC
A suplementação com probióticos foi iniciada 1 mês antes do parto e continuou por 6 meses após o
nascimento da criança;
O desenvolvimento de sintomas alérgicos pelas crianças foi avaliado após 4, 10 e 18 meses de
idade.
Resultados
 O risco de desenvolvimento de eczema/dermatite atópica durante os primeiros

18 meses de vida foi significativamente reduzido entre as crianças cujas mães
receberam suplementação de probióticos;
 Análises da composição fecal indicaram alterações da microbiota após 4 meses
entre as crianças que desenvolveram eczema/dermatite atópica;
 A proporção de Proteobacteria foi significativamente menor nas mães (no
momento do parto) que receberam a suplementação.
Referências
Enomoto T1, Sowa M2, Nishimori K2, Shimazu S3, Yoshida A4, Yamada K5, Furukawa F6, Nakagawa T7, Yanagisawa N8, Iwabuchi N9, Odamaki T9, Abe F9, Nakayama J10, Xiao JZ9.
Effects of bifidobacterial supplementation to pregnant women and infants in the prevention of allergy development in infants and on fecal microbiota. Allergol Int. 2014 Dec;63(4):575-85. doi:
10.2332/allergolint.13-OA-0683. Epub 2014 Jul 25.
Formulações
Formulário 1
Rinite Alérgica / Rinopatia
Rinite Alérgica Persistente
Cápsulas de L. paracasei
Lactobacillus paracasei......1 x 109 UFC*


médica.
*Dose usual
Rinite Alérgica Sazonal
Cápsulas de B. lactis
Bifidobacterium lactis..........1 x 109 UFC*


médica.
*Dose usual.
Alergia em Pacientes Rinopáticos
Iogurte Enriquecido com Probióticos
Streptococcus thermophilus.....2 x 109 UFC

Lactobacillus bulgaricus............2 x 107 UFC
Lactobacillus acidophilus..........2 x 107 UFC
Bifidobacterium spp..................2 x 107 UFC
Base para Iogurte qsp....................1 Sachê

médica.
Formulário 2
Prevenção / Tratamento de Alergias em Crianças
Rinite Alérgica/Asma Infantil - Redução dos Sinais Clínicos
Cápsulas de L. gasseri
Lactobacillus gasseri............2 x 109 UFC


Rinite Alérgica/Asma Infantil - Modulação da Resposta Imune
Cápsulas de L. casei

Base para Iogurte qsp...............1 Sachê

médica.
Alergia às Proteínas do Leite de Vaca
Bifidobacterium lactis................1 x 109 UFC

Streptococcus thermophilus.....1 x 108 UFC
Suplementação Pré-natal para Prevenção de Alergias em Crianças
Bifidobacterium breve............2,5 x 109 UFC

Bifidobacterium longu............2,5 x 109 UFC
Excipiente qsp.............................1 Cápsula

médica.
Probióticos e Alterações
Urogenitais
Vaginose Bacteriana
Probióticos Orais Melhoram a Resposta ao

Tratamento Antimicrobiano
Objetivo do Estudo
Um estudo conduzido por Martinez et al. (2009) foi realizado com a finalidade de avaliar
a eficácia dos probióticos em proporcionar um complemento eficaz ao tratamento
antimicrobiano e melhorar as taxas de eficácia e cura da vaginose bacteriana.
Nesse estudo, 64 pacientes com vaginose bacteriana receberam, durante 4

semanas, pela manhã:
Grupo I (n=95)
Grupo II (n=95)
Tinidazol 2 g (Dose única)
Tinidazol 2 g (dose única)
+
+
2 cápsulas contendo:
Placebo
L. rhamnosus e L. reuteri
 No final do tratamento, o grupo probiótico teve uma taxa de cura

significativamente mais elevada de BV (87,5%) do que no grupo placebo (50,0
%);
 De acordo com os escores de Nugent (método de avaliação do perfil
bacteriológico da vagina), mais mulheres foram avaliadas com microbiota
"normal" vaginal no grupo probiótico (75,0% vs. 34,4% no grupo placebo,
p=0,011).
Este estudo comprova que Lactobacillus probióticos proporcionam benefícios para

mulheres que estão sendo tratadas com terapia antimicrobiana por um quadro
infeccioso de vaginose bacteriana.
Referências
Martinez RC1, Franceschini SA , Patta MC , Quintana SM , Gomes AC, De Martinis CE , Reid G. Improved cure of bacterial vaginosis with single dose of tinidazole (2 g), Lactobacillus
rhamnosus GR-1, and Lactobacillus reuteri RC-14: a randomized, double-blind, placebo-controlled trial. Can J Microbiol. 2009 Feb;55(2):133-8. doi: 10.1139/w08-102.
Vaginose Bacteriana
Lactobacillus casei Tópico Restaura a Microbiota
Vaginal Alterada
Objetivo do Estudo
Um estudo conduzido por Petricevic e Witt (2008) teve como objetivo avaliar os efeitos
sobre a microbiota vaginal após o uso de probióticos no tratamento da vaginose
bacteriana.
Nesse estudo, 190 pacientes foram randomizadas para receber por 7 dias, após
o término da terapia com antibióticos, a seguinte posologia:
Grupo I (n=95)
Lactobacillus casei 1 x 109 UFC Grupo II (n=95)
Aplicação vaginal diária, por 7 dias Placebo
 De acordo com os resultados, 83% das mulheres do grupo I e 35% do grupo II

mostraram redução dos escores de Nugent em cinco graus;
 O número de mulheres que respondeu ao tratamento foi altamente significativo
no grupo I;
 A diferença médica dos escores de Nugent entre o swab inicial e final foi de 6,61
no grupo I e 4,13 no grupo II;
Os resultados sugerem que a restauração da microbiota vaginal após o tratamento da

vaginose bacteriana com antibióticos foi aumentada de maneira significativa após a
aplicação vaginal de probióticos.
Referências
Petricevic L1, Witt A. The role of Lactobacillus casei rhamnosus Lcr35 in restoring the normal vaginal flora after antibiotic treatment of bacterial vaginosis. BJOG. 2008 Oct;115(11):1369-74.
doi: 10.1111/j.1471-0528.2008.01882.x.
Candidíase Vulvovaginal
Associação Probiótica Aumenta a Taxa de Cura
Objetivo do Estudo
Um estudo conduzido por Martinez et al. (2009) teve como objetivo avaliar os efeitos da
suplementação com Lactobacillus no tratamento da candidíase vulvovaginal.
Nesse estudo, 55 mulheres com candidíase vulvovaginal com teste positivo

para Candida spp. foram selecionadas e divididas em 2 grupos para receber por
4 semanas, pela manhã:
Grupo I
Fluconazol - 150 mg - dose única Grupo II (n=95)
+ Fluconazol - 150 mg - dose única
Lactobacillus rhamonus - 1 x 109 UFC +
L. reuteri - 1 x 109 UFC Placebo
2 cápsulas
 Após 4 semanas, o grupo que recebeu probióticos apresentou redução de

sintomas associados à candidíase vaginal, como prurido e ardência;
 Houve também redução da detecção de leveduras após testes de cultura no

grupo I.
Este estudo fornece evidências que a adição de probióticos à terapia convencional

para candidíase promove melhora mais significativa dos sintomas, aumentando a taxa
de cura.
Referências
Martinez RC1, Franceschini SA, Patta MC, Quintana SM, Candido RC, Ferreira JC, De Martinis EC, Reid G. Improved treatment of vulvovaginal candidiasis with fluconazole plus probiotic
BIFÓRMULA
Lactobacillus FARMÁCIA
rhamnosus GR-1 DE MANIPULAÇÃO
and Lactobacillus reuteri RC-14. Lett–Appl
MOEMA:
Microbiol.Av. Ibirapuera,
2009 1898doi:
Mar;48(3):269-74. - SP10.1111/j.1472-765X.2008.02477.x.
- Tel: 5051-2601 - Fax: 5052-5114
Epub 2009- Feb
WhatsApp
2. 11 62
Atrofria Vulvovaginal
Lactobacillus acidophilus Melhora Sintomas
Urogenitais
Objetivo do Estudo
Um estudo conduzido por Capobianco et al. (2013) teve como objetivo avaliar se a
combinação de Lactobacillus acidophillus e estriol, em conjunto com a reabilitação do
assoalho pélvico, exerce efeitos sobre os sintomas da atrofia vulgovaginal em pós-
menopausadas.
Nesse estudo, 136 pacientes foram divididas em dois grupos para receber a
seguinte posologia:
Grupo I (n=68)
Óvulo vaginal com Estriol 30 mcg
+
Óvulos vaginais contendo: Grupo II (n=68)
Lactobacillus acidophillus 1x108 UFC Óvulo vaginal contendo:
Aplicação diária por 2 semanas, seguida da Estriol 30 mcg
aplicação de 2 óvulos, 1 vez por semana
durante 6 meses.
 De acordo com os resultados, as pacientes do grupo 1 apresentaram melhora

de 76,27% na atrofia vaginal, enquanto as pacientes do grupo 2 apresentaram
melhora de 41,27%;
 O número de mulheres que respondeu ao tratamento foi altamente significativo;
 Nos pacientes do grupo 1 houve uma significativa melhora nos exames
colposcópicos e houve um aumento significativo na pressão uretral máxima.
Os resultados sugerem que a aplicação de óvulos vaginas com probióticos pode ser
efetiva e considerada como alternativa para o tratamento e prevenção dos sintomas
urogenitais em mulheres pós-menopausadas.
Referências
Capobianco G1, Wenger JM, Meloni GB, Dessole M, Cherchi PL, Dessole S. Triple therapy with Lactobacilli acidophili, estriol plus pelvic floor rehabilitation for symptoms of urogenital aging
in postmenopausal women. Arch Gynecol Obstet. 2014 Mar;289(3):601-8. doi: 10.1007/s00404-013-3030-6. Epub 2013 Sep 22.
Alteração da Microbiota Vaginal
Associação Probiótica Restaura a Microflora em
Pós-menopausadas
Objetivo do Estudo
Um estudo conduzido por Petricevic et al. (2008) teve como objetivo avaliar a influência
da suplementação oral de probióticos sobre a qualidade da microflora vaginal em
mulheres pós-menopausadas.
Nesse estudo, 72 mulheres pós-menopausadas com escore de Nugent entre 4 e

6 foram selecionadas e divididas em 2 grupos, para receber por 14 dias:
Grupo I (n=35)
Grupo II (n=37)
Cápsulas contendo:
Placebo
Lactobacillus rhamnosus - 2,5 x 109 UFC
Lactobacillus reuteri - 2,5 x 109 UFC
Redução de até 2 graus no

escore de Nugent
Grupo I 21 de 35 (60%)
Grupo II 6 de 37 (16%)
Os resultados sugerem que a administração de probióticos é uma alternativa eficaz

para restaurar a microflora vaginal alterada na pós-menopausa.
Referências
Petricevic L1, Unger FM, Viernstein H, Kiss H. Randomized, double-blind, placebo-controlled study of oral lactobacilli to improve the vaginal flora of postmenopausal women. Eur J Obstet
Gynecol Reprod Biol. 2008 Nov;141(1):54-7. doi: 10.1016/j.ejogrb.2008.06.003. Epub 2008 Aug 12.
Formulações
Formulário 1
Vaginose Bacteriana / Candidíase Vulvovaginal
Vaginose Bacteriana - Tratamento Oral
Cápsulas de Probióticos
Lactobacillus rhamnosus....1 x 109 UFC*

Lactobacillus reuteri............1 x 109 UFC*

médica.
*Dose usual
Vaginose Bacteriana - Tratamento Tópico
Supositório com L. casei

Base para Óvulo qsp......................1 UN
Aplicação vaginal diária por 7 dias ou conforme orientação

médica.
Candidíase Vulvovaginal - Tratamento Oral
Cápsulas de Lactobacillus
Lactobacillus rhamnosus..........1 x 109 UFC

Lactobacillus reuteri..................1 x 109 UFC
Excipiente qsp.............................1 Cápsula

médica.
Formulário 2
Atrofia Vulvovaginal / Restauração da Microbiota
Local
Atrofia Vulvovaginal - Tratamento Tópico para Melhora dos Sintomas
Óvulos com Probióticos
Lactobacillus acidophilus......1 x 108 UFC

Base para Óvulo qsp......................1 UN
Administrar 1 óvulo ao dia por 2 semanas, seguido de 2

óvulos 1 vez por semana durante 6 meses ou conforme
Restauração da Microbiota Vaginal em Pós -menopausadas
Cápsulas de Lactobacillus
Lactobacillus rhamnosus...2,5 x 109 UFC

Lactocbacillus reuteri.........2,5 x 109 UFC

médica.
Probióticos e Neurologia
Depressão
Pool de Lactobacillus Reduz Sintomas Associados
Depressão
Objetivo do Estudo
Um estudo conduzido por Steenbergen et al. (2015) teve como objetivo avaliar se um
pool de probióticos age regulando o processo de disbiose intestinal e, através do eixo
intestino-cérebro, reduz os sintomas depressivos.
Estudo clínico e randomizado foi realizado com 40 pacientes que

apresentavam quadro depressivo. Os pacientes foram divididos em dois grupos
para receber a seguinte posologia por 4 semanas:
Grupo I
Grupo II
2,5 x 109 UFC, 2 vezes ao dia com:
Placebo
B. bifidum, B. lactis, L. acidophilus, L. brevis,
L. casei, L. salivarius, L. lactis
 Os pacientes tratados com a suplementação probiótica por 4 semanas

mostraram uma redução significativa nos sintomas relacionados à depressão,
com melhora do humor e da agressividade.
Os resultados deste estudo foram os primeiros a evidenciar que a ingestão de

probióticos pode auxiliar na melhora de alguns sintomas relacionados à depressão
como a agressão e o humor.
Referências
Steenbergen L1, Sellaro R2, van Hemert S3, Bosch JA4, Colzato LS5. A randomized controlled trial to test the effect of multispecies probiotics on cognitive reactivity to sad mood. Brain
BIFÓRMULA
Behav Immun. FARMÁCIA
2015 Aug;48:258-64. DE MANIPULAÇÃO –Epub
doi: 10.1016/j.bbi.2015.04.003. MOEMA: Av.
2015 Apr 7. Ibirapuera, 1898 - SP - Tel: 5051-2601 - Fax: 5052-5114 - WhatsApp 11 68
Formulações
Formulário 1
Depressão
Pool de Probióticos Coadjuvantes no Tratamento da Depressão - Melhora do

Humor e da Agressividade
Bifidobacterium bifidum.....3,5 x 108 UFC

Bifidobacterium lactis.........3,5 x 108 UFC
Lactobacillus acidophilus...3,5 x 108 UFC
Lactobacillus brevis...........3,5 x 108 UFC
Lactobacillus casei............3,5 x 108 UFC
Lactobacillus salivarius.......3,5 x 108 UFC
Bifidobacterium lactis.........3,5 x 108 UFC

médica.
Abstracts
J Food Sci Technol. 2015 Dec;52(12):7577-7587. Epub 2015 Jul 22.
Probiotics, prebiotics and synbiotics- a review.
Pandey KR1, Naik SR1, Vakil BV1.
Author information
Abstract
The health benefits imparted by probiotics and prebiotics as well as synbiotics have been
the subject of extensive research in the past few decades. These food supplements
termed as functional foods have been demonstrated to alter, modify and reinstate the
pre-existing intestinal flora. They also facilitate smooth functions of the intestinal
environment. Most commonly used probiotic strains are: Bifidobacterium, Lactobacilli, S.
boulardii, B. coagulans. Prebiotics like FOS, GOS, XOS, Inulin; fructans are the most
commonly used fibers which when used together with probiotics are termed synbiotics
and are able to improve the viability of the probiotics. Present review focuses on
composition and roles of Probiotics, Prebiotics and Synbiotics in human health.
Furthermore, additional health benefits like immune-modulation, cancer prevention,
inflammatory bowel disease etc. are also discussed. Graphical abstractPictorial summary
of health benefits imparted by probiotics, prebiotics and synbiotics.
KEYWORDS:
Cancer; Cardiovascular diseases; Intestinal disorders; Prebiotics; Probiotics; Synbiotics
PMID: 26604335 [PubMed - as supplied by publisher] PMCID: PMC4648921 [Available
on 2016-12-01]
Nutr J. 2014 Jul 24;13:75. doi: 10.1186/1475-2891-13-75.

Effect of yogurt containing polydextrose, Lactobacillus acidophilus NCFM and
Bifidobacterium lactis HN019: a randomized, double-blind, controlled study in chronic
constipation.
Magro DO1, de Oliveira LM, Bernasconi I, Ruela Mde S, Credidio L, Barcelos IK, Leal RF,
Ayrizono Mde L, Fagundes JJ, Teixeira Lde B, Ouwehand AC, Coy CS.
Author information
Abstract
BACKGROUND:
Constipation is a frequent complaint and the combination of a prebiotic and probiotics
could have a potentially synergic effect on the intestinal transit. The present study
therefore aims to investigate the combination of polydextrose (Litesse), L. acidophilus
NCFM® and B. lactis HN019 in a yogurt on intestinal transit in subjects who suffer from
constipation.
METHODS:
Patients with constipation were randomly divided into two groups, Control Group (CG)
and Treatment Group (TG), and had to eat 180 ml of unflavored yogurt every morning for
14 days. Those in the CG received only yogurt, while the TG received yogurt containing
polydextrose, L. acidophilus NCFM (ATCC 700396) and B. lactis HN019 (AGAL
NM97/09513).
RESULTS:
Favourable clinical response was assessed since Agachan score had a significant
reduction at the end of the study in both groups and tended to be better in the TG. The
subjects in the treatment group also had a shorter transit time at the end of the
intervention compared to the control group (p = 0.01).
CONCLUSION:
The product containing yogurt with polydextrose, B. lactis HN019 and L. acidophilus
NCFM® significantly shortened colonic transit time after two weeks in the TG compared
to CG and may be an option for treatment of constipation.
PMID: 25056655 [PubMed - indexed for MEDLINE] PMCID: PMC4113128 Free PMC
Article
J Clin Gastroenterol. 2011 Oct;45(9):785-9. doi: 10.1097/MCG.0b013e3182166a42.

A randomized, double-blind, placebo-controlled pilot study of Lactobacillus reuteri ATCC
55730 for the prevention of antibiotic-associated diarrhea in hospitalized adults.
Cimperman L1, Bayless G, Best K, Diligente A, Mordarski B, Oster M, Smith M, Vatakis F,
Wiese D, Steiber A, Katz J.
Author information
Abstract
GOALS:
The purpose of the study was to evaluate Lactobacillus reuteri for the prevention of
antibiotic-associated diarrhea (AAD) in hospitalized adults.
BACKGROUND:
AAD is a problem in hospitalized adults, contributing to increased length of stay, cost,
and mortality. Probiotics have been proposed as a way to prevent AAD. L. reuteri
decreases acute infectious diarrhea in children; however, L. reuteri has never been
evaluated for the prevention of AAD.
STUDY:
In a randomized, double-blind, placebo-controlled pilot study, in-patients receiving
antibiotics were given L. reuteri 1×10 colony-forming units twice daily or an identical
placebo for 4 weeks. Stool frequency, consistency, and gastrointestinal symptoms were
monitored during the 4-week treatment period and during a 2-week follow-up period.
RESULTS:
A total of 31 patients were enrolled. Eight patients were excluded in the data analysis
because of length of study participation less than 14 days. Mean age was 51 ± 18 years;
63% were female and 37% male. Most frequent primary diagnosis was pneumonia (20%),
followed by abscess (10%), chronic obstructive pulmonary disease (6.7%), and bronchitis
(6.7%). Thirteen patients received L. reuteri and 10 received placebo. Patients treated with
L. reuteri had a significantly lower frequency of diarrhea compared with placebo (50% in
the placebo group vs. 7.7% in the probiotic group, P=0.02). There were no differences in
the frequency or severity of gastrointestinal symptoms.
CONCLUSIONS:
In this placebo-controlled, pilot study, L. reuteri twice daily for 4 weeks significantly
decreased AAD among hospitalized adults. L. reuteri was safe and well tolerated.
PMID: 21552138 [PubMed - indexed for MEDLINE]
Indian J Med Res. 2014 Mar;139(3):379-85.

Lactobacillus GG for treatment of acute childhood diarrhoea: an open labelled,
randomized controlled trial.
Aggarwal S, Upadhyay A1, Shah D, Teotia N, Agarwal A, Jaiswal V.
Author information
Abstract
BACKGROUND & OBJECTIVES:
Randomized controlled trials in developed countries have reported benefits of
Lactobacillus GG (LGG) in the treatment of acute watery diarrhoea, but there is paucity of
such data from India. The study was aimed to evaluate the efficacy and safety of
Lactobacillus GG in the treatment of acute diarrhoea in children from a semi-urban city in
north India.
METHODS:
In this open labelled, randomized controlled trial 2000 children with acute watery
diarrhoea, aged between 6 months to 5 years visiting outpatient department and
emergency room of a teaching hospital in north India were enrolled. The children were
randomized into receiving either Lactobacillus GG in dose of 10 billion cfu/day for five
days or no probiotic medication in addition to standard WHO management of diarrhoea.
Primary outcomes were duration of diarrhoea and time to change in consistency of
stools.
RESULTS:
Median (inter quartile range) duration of diarrhoea was significantly shorter in children in
LGG group [60 (54-72) h vs. 78 (72-90) h; P<0.001]. Also, there was faster improvement
in stool consistency in children receiving Lactobacillus GG than control group [36 (30-36)
h vs. 42 (36-48) h; P<0.001]. There was significant reduction in average number of
stools per day in LGG group (P<0.001) compared to the control group. These benefits
were seen irrespective of rotavirus positivity in stool tests.
INTERPRETATION & CONCLUSIONS:

Our results showed that the use of Lactobacillus GG in children with acute diarrhoea
resulted in shorter duration and faster improvement in stool consistency as compared to
the control group.
Comment in
Probiotics for diarrhoea. [Indian J Med Res. 2014]
Article
Indian J Med Res. 2014 Mar;139(3):379-85.

Lactobacillus GG for treatment of acute childhood diarrhoea: an open labelled,
randomized controlled trial.
Aggarwal S, Upadhyay A1, Shah D, Teotia N, Agarwal A, Jaiswal V.
Author information
Abstract
BACKGROUND & OBJECTIVES:
Randomized controlled trials in developed countries have reported benefits of
Lactobacillus GG (LGG) in the treatment of acute watery diarrhoea, but there is paucity of
such data from India. The study was aimed to evaluate the efficacy and safety of
Lactobacillus GG in the treatment of acute diarrhoea in children from a semi-urban city in
north India.
METHODS:
In this open labelled, randomized controlled trial 2000 children with acute watery
diarrhoea, aged between 6 months to 5 years visiting outpatient department and
emergency room of a teaching hospital in north India were enrolled. The children were
randomized into receiving either Lactobacillus GG in dose of 10 billion cfu/day for five
days or no probiotic medication in addition to standard WHO management of diarrhoea.
Primary outcomes were duration of diarrhoea and time to change in consistency of
stools.
RESULTS:
Median (inter quartile range) duration of diarrhoea was significantly shorter in children in
LGG group [60 (54-72) h vs. 78 (72-90) h; P<0.001]. Also, there was faster improvement
in stool consistency in children receiving Lactobacillus GG than control group [36 (30-36)
h vs. 42 (36-48) h; P<0.001]. There was significant reduction in average number of
stools per day in LGG group (P<0.001) compared to the control group. These benefits
were seen irrespective of rotavirus positivity in stool tests.
INTERPRETATION & CONCLUSIONS:

Our results showed that the use of Lactobacillus GG in children with acute diarrhoea
resulted in shorter duration and faster improvement in stool consistency as compared to
the control group.
Comment in
Probiotics for diarrhoea. [Indian J Med Res. 2014]
Article
J Clin Gastroenterol. 2012 Mar;46(3):220-7. doi: 10.1097/MCG.0b013e31823712b1.

The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in
diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-
controlled trial.
Ki Cha B1, Mun Jung S, Hwan Choi C, Song ID, Woong Lee H, Joon Kim H, Hyuk J,
Kyung Chang S, Kim K, Chung WS, Seo JG.
Author information
Abstract
BACKGROUND:
The clinical effect of probiotics on irritable bowel syndrome (IBS) is still controversial.
AIMS:
We aimed to evaluate the effects of a probiotic mixture on IBS symptoms and the
composition of fecal microbiota in patients with diarrhea-dominant IBS (D-IBS).
METHODS:
Fifty patients with D-IBS were randomized into placebo or probiotic mixture (Lactobacillus
acidophilus, Lactobacillus plantarum, Lactobacillus rhamnosus, Bifidobacterium breve,
Bifidobacterium lactis, Bifidobacterium longum, and Streptococcus thermophilus 1.0×10
CFU) groups. Treatment was taken daily for 8 weeks. The primary outcome was
adequate relief (AR) of overall IBS symptoms, which was assessed weekly for 10 weeks.
A responder was defined as a patient who experienced AR for at least half of the 10-week
study period. Secondary outcomes included the effects on individual symptoms, stool
parameters, and IBS quality of life. The fecal flora compositions were analyzed by
polymerase chain reaction denaturing gradient gel electrophoresis (DGGE).
RESULTS:
The proportion of AR was consistently higher in the probiotics group than in the placebo
group throughout the 10-week period (P<0.05). The proportion of responders was
significantly higher in the probiotics group than in the placebo group (48% vs. 12%,
P=0.01). Stool consistency improved significantly in the probiotics group compared with
the placebo group. Percent changes in individual symptom scores were similar in the 2
groups, but IBS quality of life improvement tended to be higher in the probiotics group.
Comparison of denaturing gradient gel electrophoresis profiles of fecal flora showed that
the concordance rate between bacterial compositions before and after treatment was
significantly higher in the probiotics group than in the placebo group (69.5% vs. 56.5%,
P=0.005).
CONCLUSIONS:
The probiotic mixture was effective in providing AR of overall IBS symptoms and
improvement of stool consistency in D-IBS patients, although it had no significant effect
on individual symptoms. The therapeutic effect of probiotics is associated with the
stabilization of intestinal microbiota.
J Gastroenterol Hepatol. 2014 Jan;29(1):52-9. doi: 10.1111/jgh.12322.

Effect of multispecies probiotics on irritable bowel syndrome: a randomized, double-
blind, placebo-controlled trial.
Yoon JS1, Sohn W, Lee OY, Lee SP, Lee KN, Jun DW, Lee HL, Yoon BC, Choi HS,
Chung WS, Seo JG.
Author information
Abstract
BACKGROUND AND AIM:
The efficacy of treatment with multispecies probiotics on irritable bowel syndrome (IBS)
symptoms and the alterations of gut microbiota in patients who have taken probiotics
were investigated.
METHODS:
This randomized, double-blind, placebo-controlled trial involved 49 IBS patients
(probiotics: 25, placebo: 24) diagnosed according to the Rome III criteria. Patients were
randomly assigned to two groups: either to receive multispecies probiotics (a mixture of
Bifidobacterium longum, B. bifidum, B. lactis, Lactobacillus acidophilus, L. rhamnosus,
and Streptococcus thermophilus) twice a day for 4 weeks or to receive a placebo twice a
day for 4 weeks. The primary efficacy end-point was the proportion of participants whose
IBS symptoms were substantially relieved at week 4. Secondary end-points were the
intensity of abdominal pain/discomfort, bloating, stool frequency/consistency, alterations
in fecal microflora over the 4 weeks. Fecal microflora were analyzed in 34 patients
(probiotics: 17, placebo: 17) by quantitative real-time polymerase chain reaction assays.
RESULTS:
The proportion of patients whose IBS symptoms were substantially relieved at week 4
was significantly higher in the probiotics group than in the placebo group: 68.0% (17/25)
versus 37.5% (9/24) (P < 0.05). Secondary end-points such as improvement in
abdominal pain/discomfort and bloating occurred in the probiotics group but not in the
placebo group. Fecal analysis revealed that B. lactis, L. rhamnosus, and S. thermophilus
had increased significantly in the probiotics group after 4 weeks and that B. lactis had
increased in the placebo group.
CONCLUSIONS:
Multispecies probiotics are effective in IBS patients and induce the alterations in the
composition of intestinal microbiota.
© 2013 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing

Asia Pty Ltd.
KEYWORDS:
irritable bowel syndrome; microbiota; probiotics
J Neurogastroenterol Motil. 2011 Jul;17(3):252-66. doi: 10.5056/jnm.2011.17.3.252.

Epub 2011 Jul 13.
Irritable bowel syndrome, gut microbiota and probiotics.
Lee BJ1, Bak YT.
Author information
Abstract
Irritable bowel syndrome (IBS) is a complex disorder characterized by abdominal
symptoms including chronic abdominal pain or discomfort and altered bowel habits. The
etiology of IBS is multifactorial, as abnormal gut motility, visceral hypersensitivity,
disturbed neural function of the brain-gut axis and an abnormal autonomic nervous
system are all implicated in disease progression. Based on recent experimental and
clinical studies, it has been suggested that additional etiological factors including low-
grade inflammation, altered gut microbiota and alteration in the gut immune system play
important roles in the pathogenesis of IBS. Therefore, therapeutic restoration of altered
intestinal microbiota may be an ideal treatment for IBS. Probiotics are live organisms that
are believed to cause no harm and result in health benefits for the host. Clinical efficacy
of probiotics has been shown in the treatment or prevention of some gastrointestinal
inflammation-associated disorders including traveler's diarrhea, antibiotics-associated
diarrhea, pouchitis of the restorative ileal pouch and necrotizing enterocolitis. The
molecular mechanisms, as cause of IBS pathogenesis, affected by altered gut
microbiota and gut inflammation-immunity are reviewed. The effect of probiotics on the
gut inflammation-immune systems and the results from clinical trials of probiotics for the
treatment of IBS are also summarized.
KEYWORDS:
Immunity; Inflammation; Irritable bowel syndrome; Microbiota; Probiotics
PMID: 21860817 [PubMed] PMCID: PMC3155061
J Gastroenterol Hepatol. 2007 Aug;22(8):1199-204.

High dose probiotic and prebiotic cotherapy for remission induction of active Crohn's
disease.
Fujimori S1, Tatsuguchi A, Gudis K, Kishida T, Mitsui K, Ehara A, Kobayashi T, Sekita Y,
Seo T, Sakamoto C.
Author information
Abstract
BACKGROUND:
Clinical trials of probiotic treatment for Crohn's disease (CD) have yielded conflicting
results. This study assessed the clinical usefulness of combined probiotic and prebiotic
therapy in the treatment of active CD.
METHOD:
Ten active CD outpatients without history of operation for CD were enrolled. Their mean
(+/-SD) age was 27 +/- 7 years and the main symptoms presented were diarrhea and
abdominal pain. Patients' initial therapeutic regimen of aminosalicylates and prednisolone
failed to achieve remission. Patients were thus initiated on a synbiotic therapy, consisting
of both probiotics (75 billion colony forming units [CFU] daily) and prebiotics (psyllium 9.9
g daily). Probiotics mainly comprised Bifidobacterium and Lactobacillus. Patients were
free to adjust their intake of probiotics or prebiotics throughout the trial. Crohn's disease
activity index (CDAI), International Organization for the Study of Inflammatory Bowel
Disease (IOIBD) score and blood sample variables were evaluated and compared before
and after the trial.
RESULTS:
The duration of the trial was 13.0 +/- 4.5 months. By the end of therapy, each patient had
taken a 45 +/- 24 billion CFU daily probiotic dose, with six patients taking an additional
7.9 +/- 3.6 g daily psyllium dose. Seven patients had improved clinical symptoms
following combined probiotic and prebiotic therapy. Both CDAI and IOIBD scores were
significantly reduced after therapy (255-136, P = 0.009; 3.5-2.1, P = 0.03, respectively).
Six patients had a complete response, one had a partial response, and three were non-
responders. Two patients were able to discontinue their prednisolone therapy, while four
patients decreased their intake. There were no adverse events.
CONCLUSION:
High-dose probiotic and prebiotic cotherapy can be safely and effectively used for the
treatment of active CD.
Aliment Pharmacol Ther. 2006 Jun 1;23(11):1567-74.
Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis.
Zocco MA1, dal Verme LZ, Cremonini F, Piscaglia AC, Nista EC, Candelli M, Novi M,
Rigante D, Cazzato IA, Ojetti V, Armuzzi A, Gasbarrini G, Gasbarrini A.
Author information
Abstract
BACKGROUND:
Aminosalicylates are the mainstay of therapy to prevent relapse of quiescent ulcerative
colitis. The rationale for using probiotics is based on the evidence implicating intestinal
bacteria in the pathogenesis of this disorder.
AIM:
To evaluate the efficacy of Lactobacillus GG alone or in combination with mesalazine vs.
mesalazine as maintenance treatment in ulcerative colitis.
PATIENTS AND METHODS:

187 ulcerative colitis patients with quiescent disease were randomized to receive
Lactobacillus GG 18 x 10(9) viable bacteria/day (65 patients), mesalazine 2400 mg/day
(60 patients) or Lactobacillus GG + mesalazine (62 patients). Disease activity index,
endoscopic and histological scores were determined at 0, 6 and 12 months and in case
of relapse. The primary end point was to evaluate sustained remission.
RESULTS:
Overall analysis showed no difference in relapse rate at 6 (P = 0.44) and 12 months (P =
0.77) among the three treatment groups. However, the treatment with Lactobacillus GG
seems to be more effective than standard treatment with mesalazine in prolonging the
relapse-free time (P < 0.05).
CONCLUSIONS:
Lactobacillus GG seems to be effective and safe for maintaining remission in patients
with ulcerative colitis, and it could represent a good therapeutic option for preventing
relapse in this group of patients.
Gut Microbes. 2013 Jul-Aug;4(4):325-39. doi: 10.4161/gmic.25487. Epub 2013 Jun 21.
Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut.
Groeger D1, O'Mahony L, Murphy EF, Bourke JF, Dinan TG, Kiely B, Shanahan F, Quigley
EM.
Author information
Abstract
Certain therapeutic microbes, including Bifidobacteria infantis (B. infantis) 35624 exert
beneficial immunoregulatory effects by mimicking commensal-immune interactions;
however, the value of these effects in patients with non-gastrointestinal inflammatory
conditions remains unclear. In this study, we assessed the impact of oral administration
of B. infantis 35624, for 6‒8 weeks on inflammatory biomarker and plasma cytokine levels
in patients with ulcerative colitis (UC) (n = 22), chronic fatigue syndrome (CFS) (n = 48)
and psoriasis (n = 26) in three separate randomized, double-blind, placebo-controlled
interventions. Additionally, the effect of B. infantis 35624 on immunological biomarkers in
healthy subjects (n = 22) was assessed. At baseline, both gastrointestinal (UC) and non-
gastrointestinal (CFS and psoriasis) patients had significantly increased plasma levels of
C-reactive protein (CRP) and the pro-inflammatory cytokines tumor necrosis factor α
(TNF-α) and interleukin-6 (IL-6) compared with healthy volunteers. B. infantis 35624
feeding resulted in reduced plasma CRP levels in all three inflammatory disorders
compared with placebo. Interestingly, plasma TNF-α was reduced in CFS and psoriasis
while IL-6 was reduced in UC and CFS. Furthermore, in healthy subjects, LPS-stimulated
TNF-α and IL-6 secretion by peripheral blood mononuclear cells (PBMCs) was
significantly reduced in the B. infantis 35624-treated groups compared with placebo
following eight weeks of feeding. These results demonstrate the ability of this microbe to
reduce systemic pro-inflammatory biomarkers in both gastrointestinal and non-
gastrointestinal conditions. In conclusion, these data show that the immunomodulatory
effects of the microbiota in humans are not limited to the mucosal immune system but
extend to the systemic immune system.
KEYWORDS:
B. infantis35624; C-reactive protein; immunity; inflammation; microbiota
PMID: 23842110 [PubMed - indexed for MEDLINE] PMCID: PMC3744517
BMC Surg. 2013;13 Suppl 2:S57. doi: 10.1186/1471-2482-13-S2-S57. Epub 2013 Oct 8.
Early postoperative administration of probiotics versus placebo in elderly patients
undergoing elective colorectal surgery: a double-blind randomized controlled trial.
Pellino G, Sciaudone G, Candilio G, Camerlingo A, Marcellinaro R, De Fatico S, Rocco F,
Canonico S, Riegler G, Selvaggi F.
Abstract
BACKGROUND:
Perioperative prophylactic antibiotic treatment significantly influences intestinal microflora,
resulting in impaired bowel functioning in some patients, sometimes requiring further
investigations. This may lead to a worse health-related quality of life (HRQoL). Probiotics
administrated in the early post-operative period may help avoiding such nuisances in
older people.
METHODS:
We prospectively enrolled patients undergoing laparoscopic colorectal surgery aged over
70 years between 2005 and 2012. The study was approved by IRB. All patients received
perioperative antibiotic treatment. Patients were randomized to one of two treatment
arms: Group A patients received probiotics after surgery (VSL#3, VSL Pharmaceuticals,
Inc. USA - 900 × 109 daily, while Group B patients received a Placebo (cornstarch).
Patients were further divided in sub-groups whether ileo-caecal valve was spared or not.
Patients were followed-up every 7 days for 4 weeks. Patients daily annotated bowel
frequency, stool shape and consistency - according to Bristol's scale. HRQoL was
assessed every week by means of SF-36 questionnaire.
RESULTS:
Group A included 10 while Group B included 8 patients. One patient in each group
experienced a postoperative complication. Group A patients had fewer bowel
movements than controls, during every week. Stool consistency was higher in patients
undergoing resections including ileo-caecal valve receiving VSL#3. HRQoL gradually
increased in both groups; Group A patients had higher "social functioning" item scores at
week 1 and 4 than controls.
CONCLUSIONS:
Elderly patients undergoing resection of ileo-caecal valve may benefit from an early
probiotics administration pathway after perioperative antibiotic treatment.
World J Gastroenterol. 2012 Nov 21;18(43):6250-4. doi: 10.3748/wjg.v18.i43.6250.

Helicobacter pylori eradication: sequential therapy and Lactobacillus reuteri
supplementation.
Efrati C1, Nicolini G, Cannaviello C, O'Sed NP, Valabrega S.
Author information
Abstract
AIM:
To evaluate the role of sequential therapy and Lactobacillus reuteri (L. reuteri)
supplementation, in the eradication treatment of Helicobacter pylori (H. pylori).
METHODS:
H. pylori infection was diagnosed in 90 adult dyspeptic patients. Patients were excluded if
previously treated for H. pylori infection or if they were taking a proton pump inhibitor
(PPI), H2-receptor antagonist or antibiotics. Patients were assigned to receive one of the
following therapies: (1) 7-d triple therapy (PPI plus clarithromycin and amoxicillin or
metronidazole) plus L. reuteri supplementation during antibiotic treatment; (2) 7-d triple
therapy plus L. reuteri supplementation after antibiotic treatment; (3) sequential regimen
(5-d PPI plus amoxicillin therapy followed by a 5-d PPI, clarithromycin and tinidazole) plus
L. reuteri supplementation during antibiotic treatment; and (4) sequential regimen plus L.
reuteri supplementation after antibiotic treatment. Successful eradication therapy was
defined as a negative urea breath test at least 4 wk following treatment.
RESULTS:
Ninety adult dyspeptic patients were enrolled, and 83 (30 male, 53 female; mean age 57
± 13 years) completed the study. Nineteen patients were administered a 7-d triple
treatment: 11 with L. reuteri supplementation during and 8 after therapy. Sixty-four
patients were administered a sequential regimen: 32 with L. reuteri supplementation
during and 32 after therapy. The eradication rate was significantly higher in the sequential
group compared with the 7-d triple regimen (88% vs 63%, P = 0.01). No difference was
found between two types of PPI. No difference in eradication rates was observed
between patients submitted to L. reuteri supplementation during or after antibiotic
treatment. Compliance with therapy was excellent in all patients. No difference in adverse
effects was observed between the different antibiotic treatments and between patients
submitted to L. reuteri supplementation during and after antibiotic treatment. There was a
low incidence of adverse effects in all groups of patients with sequential therapy,
probably due to the presence of the L. reuteri supplementation.
CONCLUSION:
The sequential treatment regimen achieved a significantly higher eradication rate of H.
pylori compared with standard 7-d regimen. L. reuteri supplementation could reduce the
frequency and the intensity of antibiotic-associated side-effects.
KEYWORDS:
Eradication; Gastritis; Helicobacter pylori; Lactobacillus reuteri; Probiotics; Sequential
therapy
Medicine (Baltimore). 2015 May;94(17):e685. doi: 10.1097/MD.0000000000000685.

Probiotics for standard triple Helicobacter pylori eradication: a randomized, double-blind,
placebo-controlled trial.
Hauser G1, Salkic N, Vukelic K, JajacKnez A, Stimac D.
Author information
Abstract
The primary objective in the study is determination of efficacy of probiotic preparation as
a supportive therapy in eradication of Helicobacter pylori.The study was multicenter,
prospective, randomized, placebo controlled, and double-blind. The subjects first filled
out a specially designed questionnaire to assess the severity of the 10 symptoms, which
can be related to eradication therapy to be monitored during the trial. Each subject then
received 28 capsules of probiotic preparation or matching placebo capsules, which they
were supposed to take over the following 14 days, twice a day, at least 2 hours prior to or
after the antibiotic therapy administration.A total of 804 patients were enrolled in the trial,
of which 650 (80.85%) were included in the analysis. The results show a significantly
larger share of cured subjects in the probiotic arm versus the placebo arm (87.38% vs
72.55%; P < 0.001). Additionally, presence and intensity of epigastric pain, bloating,
flatulence, taste disturbance, loss of appetite, nausea, vomiting, heartburn, rash, and
diarrhea were monitored over the study period. At 15 days postinclusion, probiotic
treatment was found superior to placebo in 7 of 10 mentioned symptoms. Average
intensity for symptoms potentially related to antibiotic therapy was significantly higher in
the placebo group, 0.76 vs 0.55 (P < 0.001).Adding probiotics to the standard triple
therapy for H pylori eradication significantly contributes to treatment efficacy and distinctly
decreases the adverse effects of therapy and the symptoms of the underlying disease.
J Clin Diagn Res. 2015 Mar;9(3):KC01-4. doi: 10.7860/JCDR/2015/11867.5728. Epub

2015 Mar 1.
A Randomized Double-blind Controlled Trial of Lactobacillus acidophilus Plus
Bifidobacterium bifidum versus Placebo in Patients with Hypercholesterolemia.
Rerksuppaphol S1, Rerksuppaphol L2.
Author information
Abstract
BACKGROUND:
Hypercholesterolemia is a major risk factor for cardiovascular disease. Not all patients
respond well to traditional cholesterol lowering medications. Probiotics have been
evaluated for their cholesterol-lowering effects in humans with variable results. This study
was performed to evaluate the efficacy of two probiotics in lowering the serum cholesterol
of hypercholesterolemic patients.
MATERIALS AND METHODS:

A randomized double-blind controlled trial was conducted comparing placebo to
Lactobacillus acidophilus plus Bifidobacterium bifidum in patients diagnosed with
hypercholesterolemia. Placebo or probiotic capsules were taken three times daily for six
weeks. Pre- and post-treatment total cholesterol (TC), HDL-cholesterol (HDL-C), LDL-
cholesterol (LDL-C) and triglyceride (TG) levels and demographic parameters of the two
groups were compared. From a total of 70 participants, 64 completed the assigned
treatment (31 in probiotics group and 33 in the control group).The two treatment groups
were matched for age, sex, weight, height, BMI, waist and hip circumferences, and blood
pressure.
RESULTS:
Baseline evaluation revealed no difference between the probiotics group and control
group levels of TC, HDL-C, LDL-C and TG. TC levels in the probiotics group decreased
during treatment (237.2 vs. 212.7 mg/dL, p<0.05). TC and LDL-C levels in the control
group increased significantly from their baseline levels during treatment. TC (212.7 vs
252.8 mg/dL, p<0.001), HDL-C (52.0 vs 59.1 mg/dL, p=0.04) and LDL-C (153.9 vs
182.1 mg/dL, p<0.01) levels in the probiotics group were significantly lower at the end of
treatment than the corresponding levels in the control group.
CONCLUSION:
A combination of Lactobacillus acidophilus and Bifidobacterium bifidum decreased
serum total cholesterol, LDL-cholesterol and HDL-cholesterol levels in
hypercholesterolemic patients over a six week period. There was no effect on serum
triglyceride or fasting blood glucose levels.
KEYWORDS:
Cholesterol; Probiotics; Randomized controlled trial
Regul Toxicol Pharmacol. 2012 Jul;63(2):313-20. doi: 10.1016/j.yrtph.2012.04.003. Epub

2012 Apr 25.
Evaluation of clinical safety and tolerance of a Lactobacillus reuteri NCIMB 30242
supplement capsule: a randomized control trial.
Jones ML1, Martoni CJ, Di Pietro E, Simon RR, Prakash S.
Author information
Abstract
A significant number of human clinical trials have reported no adverse effects associated
with consumption of Lactobacillus reuteri (L. reuteri). In the present study, the clinical
safety and toxicology of oral ingestion of supplement capsules containing L. reuteri
NCIMB 30242 was investigated. A randomized group of 131 subjects received a dose of
2.9×10⁹ CFU L. reuteri NCIMB 30242 capsules (n=67) or placebo capsules (n=64)
twice daily for 9 weeks. Clinical chemistry and hematological parameters of safety were
analyzed. The frequency, duration and intensity of adverse events (AE)s and clinical
significance of safety parameters were recorded for both groups. No clinically significant
differences between the probiotic capsule and placebo capsule treated groups were
detected in either the blood clinical chemistry or hematology results. The frequency and
intensity of AEs was similar in the two groups. These results demonstrate that
administration of a twice daily dose of 2.9×10⁹ CFU was safe and well tolerated in the
population evaluated over 9 weeks.
Crown Copyright © 2012. Published by Elsevier Inc. All rights reserved.
Nutrition. 2014 Jul-Aug;30(7-8):831-6. doi: 10.1016/j.nut.2014.01.014. Epub 2014 Feb

15.
Bifidobacteria supplementation: effects on plasma lipid profiles in dyslipidemic children.
Guardamagna O1, Amaretti A2, Puddu PE3, Raimondi S2, Abello F4, Cagliero P4, Rossi
M2.
Author information
Abstract
OBJECTIVE:
Preclinical investigations support the use of probiotics in the treatment of
hypercholesterolemia, but clinical evidence is often contrasting. The aim of this study was
to evaluate the effects of a probiotic formulation containing three Bifidobacterium strains
on lipid profiles in children affected by primary dyslipidemia.
METHODS:
Thirty-eight children with dyslipidemia, ages 10.8 ± 2.1 y, were enrolled in a randomized,
double-blind, placebo-controlled cross-over study. After a 4-wk diet run-in period, the
children received probiotics (B. animalis subspecies lactis MB 2409, B. bifidum MB
109B, and B. longum subspecies longum BL04) or placebo for 3 mo. After 1 mo, wash-
out treatments were switched. A strict dietary evaluation concerning satured fatty acids
and cholesterol content, STEP I diet accordingly, was performed by a dietitian who
examined the weekly dietary diary at each visit.
RESULTS:
Baseline lipid profile was (mean ± SD): total cholesterol (TC) 222.8 ± 23.2 mg/dL, high-
density lipoprotein cholesterol (HDL-C) 55.8 ± 12.2 mg/dL, triglycerides (TG) 99.0 ±
61.7 mg/dL, and low-density lipoprotein cholesterol (LDL-C) 147.2 ± 21.9 mg/dL. After 3
mo of probiotic treatment, the lipid profile was: TC 211.9 ± 27.3 mg/dL, HDL-C 60.7 ±
14.2 mg/dL, TG 79.5 ± 34.5 mg/dL, and LDL-C 135.3 ± 24.2 mg/dL. Compared with
placebo, probiotics reduced TC by 3.4% (P = 0.02) and LDL-C by 3.8% (P = 0.001). No
significant dietary change occurred through the study and no relevant adverse effects
were observed.
CONCLUSIONS:
Treatment with a Bifidobacterium probiotic formulation was well tolerated and useful in
combination with to diet therapy. Children with dyslipidemia benefited from this approach,
although the results need to be confirmed by larger controlled studies.
Copyright © 2014 Elsevier Inc. All rights reserved.
KEYWORDS:
Bifidobacterium; Child; Dyslipidemia; Hypercholesterolemia; Probiotics
Korean J Fam Med. 2013 Mar;34(2):80-9. doi: 10.4082/kjfm.2013.34.2.80. Epub 2013
Mar 20.
Effect of Lactobacillus gasseri BNR17 on Overweight and Obese Adults: A Randomized,
Double-Blind Clinical Trial.
Jung SP1, Lee KM, Kang JH, Yun SI, Park HO, Moon Y, Kim JY.
Author information
Abstract
BACKGROUND:
Lactobacillus gasseri BNR17 is a type of probiotic strain isolated from human breast milk.
A study was reported regarding the fact that BNR17 was an inhibitor of obesity and
diabetic activities in the human body through previous animal experiments. This study
was furthered to investigate the effect of BNR17, a probiotic strain isolated from human
breast milk, on obese and overweight adults.
METHODS:
Sixty-two obese volunteers aged 19 to 60 with body mass index ≥ 23 kg/m(2) and
fasting blood sugar ≥ 100 mg/dL participated in a placebo controlled, randomized, and
double-blind trial. For 12 weeks, 57 participants were given either placebo or BNR17 and
were tested by measuring body fat, body weight, various biochemical parameters, vital
signs, and computed tomography at the start of the study and at weeks 4, 8, and 12. The
subjects assumed usual daily activities without having to make behavioral or dietary
modifications during the course of the study.
RESULTS:
At the 12th week, a slight reduction in body weight was noted in the BNR17 group, but
there were no significant weight changes between groups. Decrease of waist and hip
circumferences in the BNR17 group was more pronounced than those in the placebo
group. The two groups had no special or severe adverse reactions.
CONCLUSION:
Despite there being no change in behavior or diet, administration of only the supplement
of BNR17 reduced weight and waist and hip circumference. However, there were no
significant differences between the two groups. These findings warrant a subsequent
longer-term prospective clinical investigation with a large population.
KEYWORDS:
Human Breast Milk; Metabolic Disorders; Obesity; Probiotics
Br J Nutr. 2014 Apr 28;111(8):1507-19. doi: 10.1017/S0007114513003875. Epub 2013

Dec 3.
Effect of Lactobacillus rhamnosus CGMCC1.3724 supplementation on weight loss and
maintenance in obese men and women.
Sanchez M1, Darimont C2, Drapeau V3, Emady-Azar S4, Lepage M5, Rezzonico E2,
Ngom-Bru C5, Berger B2, Philippe L4, Ammon-Zuffrey C2, Leone P2, Chevrier G6, St-
Amand E6, Marette A6, Doré J1, Tremblay A1.
Author information
Abstract
The present study investigated the impact of a Lactobacillus rhamnosus CGMCC1.3724
(LPR) supplementation on weight loss and maintenance in obese men and women over
24 weeks. In a double-blind, placebo-controlled, randomised trial, each subject
consumed two capsules per d of either a placebo or a LPR formulation (1.6 × 10(8)
colony-forming units of LPR/capsule with oligofructose and inulin). Each group was
submitted to moderate energy restriction for the first 12 weeks followed by 12 weeks of
weight maintenance. Body weight and composition were measured at baseline, at week
12 and at week 24. The intention-to-treat analysis showed that after the first 12 weeks and
after 24 weeks, mean weight loss was not significantly different between the LPR and
placebo groups when all the subjects were considered. However, a significant treatment
× sex interaction was observed. The mean weight loss in women in the LPR group was
significantly higher than that in women in the placebo group (P = 0.02) after the first 12
weeks, whereas it was similar in men in the two groups (P= 0.53). Women in the LPR
group continued to lose body weight and fat mass during the weight-maintenance
period, whereas opposite changes were observed in the placebo group. Changes in
body weight and fat mass during the weight-maintenance period were similar in men in
both the groups. LPR-induced weight loss in women was associated not only with
significant reductions in fat mass and circulating leptin concentrations but also with the
relative abundance of bacteria of the Lachnospiraceae family in faeces. The present
study shows that the Lactobacillus rhamnosus CGMCC1.3724 formulation helps obese
women to achieve sustainable weight loss.
Ann Hepatol. 2013 Mar-Apr;12(2):256-62.

Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study.
Wong VW1, Won GL, Chim AM, Chu WC, Yeung DK, Li KC, Chan HL.
Author information
Abstract
BACKGROUND:
Probiotics have profound effect on nonalcoholic steatohepatitis (NASH) in animal models.
We aimed to test the hypothesis that probiotics treatment was superior to usual care in
reducing liver fat in NASH patients.
MATERIAL AND METHODS:

Patients with histology-proven NASH were randomized to receive probiotics (n = 10) or
usual care (n = 10) for 6 months. The Lepicol probiotic formula contained Lactobacillus
plantarum, Lactobacillus deslbrueckii, Lactobacillus acidophilus, Lactobacillus
rhamnosus and Bifidobacterium bifidum. The primary endpoint was change in
intrahepatic triglyceride content (IHTG), as measured by proton-magnetic resonance
spectroscopy, from baseline to month 6. Secondary endpoints included changes in liver
biochemistry and metabolic profile.
RESULTS:
IHTG decreased from 22.6 ± 8.2% to 14.9 ± 7.0% in the probiotic group (P = 0.034) but
remained static in the usual care group (16.9 ± 6.1% to 16.0 ± 6.6%; P = 0.55). Six
subjects in the probiotic group had IHTG reduced by more than 30% from baseline,
compared to 2 subjects in the usual care group (P = 0.17). The probiotic group also had
greater reduction in serum aspartate aminotransferase level (P = 0.008). On the other
hand, the use of probiotics was not associated with changes in body mass index, waist
circumference, glucose and lipid levels.
CONCLUSIONS:
Probiotics treatment may reduce liver fat and AST level in NASH patients. The therapeutic
potential of probiotics in NASH should be tested in larger studies.
J Cutan Med Surg. 2013 Mar-Apr;17(2):114-22.

Prospective, randomized, open-label trial comparing the safety, efficacy, and tolerability
of an acne treatment regimen with and without a probiotic supplement and minocycline
in subjects with mild to moderate acne.
Jung GW1, Tse JE, Guiha I, Rao J.
Author information
Abstract
BACKGROUND:
Systemic antibiotics are an effective treatment for acne vulgaris. However, intolerable side
effects may invariably occur.
OBJECTIVE:
To determine whether probiotics reduce the side effects imparted by systemic antibiotics
while working synergistically with the latter in treating inflammatory acne.
METHODS:
Forty-five 18- to 35-year-old females were randomly assigned to one of three arms in this
prospective, open-label study. Group A received probiotic supplementation, whereas
group B received only minocycline. Group C was treated with both probiotic and
minocycline. Clinical and subjective assessments were completed at baseline and during
the 2-, 4-, 8-, and 12-week follow-up visits.
RESULTS:
All patients demonstrated a significant improvement in total lesion count 4 weeks after
treatment initiation (p < .001), with continued improvement seen with each subsequent
follow-up visit (p < .01). At the 8- and 12-week follow-up visits, group C had a significant
decrease in total lesion count versus groups A (p < .001) and B (p < .01). Two patients
(13%) from group B failed to complete the study secondary to vaginal candidiasis.
CONCLUSION:
Probiotics may be considered a therapeutic option or adjunct for acne vulgaris by
providing a synergistic antiinflammatory effect with systemic antibiotics while also
reducing potential adverse events secondary to chronic antibiotic use.
J Clin Gastroenterol. 2012 Oct;46 Suppl:S56-63. doi:
10.1097/MCG.0b013e318265ef38.
Changing of fecal flora and clinical effect of L. salivarius LS01 in adults with atopic
dermatitis.
Drago L1, Toscano M, De Vecchi E, Piconi S, Iemoli E.
Author information
Abstract
GOAL:
To evaluate cytokine stimulation with 3 strains of Lactobacillus salivarius in vitro and to
assess changes in intestinal microflora and clinical improvements in adults with atopic
dermatitis (AD) induced by the strain showing the best immunomodulatory features.
BACKGROUND:
AD is a common skin disease in children and adults. It is characterized by chronic
inflammation, eczema, and increasing intestinal permeability. Various studies have shown
that patients with AD presented some modifications in the intestinal microbiota
composition; as a result, intestinal microflora is thought to have a pivotal role in this
disease.
METHODS:
Thirty-eight patients aged from 18 to 46 years with moderate/severe AD were recruited.
Subjects were randomized in a double-blind placebo-controlled study to receive active
treatment with L. salivarius LS01: probiotic (n=19) or placebo (n=19). Cytokine
production was determined by means of specific quantitative enzyme-linked
immunosorbent assays. Intestinal bacterial groups were quantified using conventional
culture techniques, whereas L. salivarius LS01 was identified using polymerase chain
reaction and pulse field gel electrophoresis.
RESULTS:
L. salivarius LS01 showed the best immunomodulatory features and it was chosen for the
second phase of the study. AD subjects showed a reduction in their SCORAD score after
probiotic treatment and a significant decrease in the staphylococci load compared with
the placebo group. Moreover, L. salivarius LS01 showed the ability to reduce the
production of Th2 cytokines, maintaining the production of Th1 cytokines stable.
CONCLUSIONS:
Treatment with the L. salivarius LS01 strain seems to positively modify clinical and
immunologic status and dermatology life quality in a group of adults affected by
moderate/severe AD, leading to a rebalancing of altered intestinal microbiota.
Ann Dermatol. 2012 May;24(2):189-93. doi: 10.5021/ad.2012.24.2.189. Epub 2012 Apr

26.
Effect of probiotics on the treatment of children with atopic dermatitis.
Yeşilova Y1, Çalka Ö, Akdeniz N, Berktaş M.
Author information
Abstract
BACKGROUND:
Atopic dermatitis, a chronic recurrent disease, is frequently encountered in clinical
practice. In the last 30 years, the prevalence of atopic dermatitis has rapidly increased
due to industrialization. Therefore, there have been attempts in recent years to find new
ways of treating and preventing atopic dermatitis.
OBJECTIVE:
In this double-blind, randomized, placebo-controlled study, a combination of
Bifidobacterium bifidum, Lactobacillus acidophilus, Lactobacillus casei, and
Lactobacillus salivarius strains were evaluated in the treatment of atopic dermatitis in
pediatric patients.
METHODS:
Forty pediatric patients (23 males and 17 females) aged 1~13 years were enrolled. One
eligible individual who was approached declined to participate. The probiotic group was
administered a probiotic complex containing B. bifidum, L. acidophilus, L. casei, and L.
salivarius for 8 weeks. The placebo group, on the other hand, was administered skim milk
powder and dextrose. All of the parameters including serum cytokines, eosinophil
cationic protein), SCORing Atopic Dermatitis (SCORAD) index, and total serum
immunoglobulin E (IgE) were measured in both the probiotic group and the placebo
group at the end of 8 weeks.
RESULTS:
Probiotic intervention in pediatric atopic dermatitis patients effectively reduced the
SCORAD index and serum cytokines interleukin (IL)-5, IL-6, interferon (IFN)-γ, and total
serum IgE levels, but did not reduce levels of serum cytokines IL-2, IL-4, IL-10, ECP, or
tumor necrosis factor-α (TNF-α) compared to the placebo group.
CONCLUSION:
Our study found probiotics to be effective in reducing atopic dermatitis patients' SCORAD
index, serum IL-5, IL-6, IFN-γ, and total serum IgE levels but not effective in reducing
serum IL-2, IL-4, IL-10, ECP, or TNF-α levels.
KEYWORDS:
Atopic dermatitis; Cytokines; Probiotics; SCORAD index
Exp Ther Med. 2015 May;9(5):1593-1596. Epub 2015 Feb 17.

Protective effect of probiotics in the treatment of infantile eczema.
Lin RJ1, Qiu LH2, Guan RZ1, Hu SJ2, Liu YY2, Wang GJ3.
Author information
Abstract
The aim of the present study was to provide evidence for the application of probiotics in
the prevention and treatment of infantile eczema by exploring changes in the intestinal
Bifidobacteria levels and the Scoring Atopic Dermatitis (SCORAD) index prior and
subsequent to treatment with probiotics in infants with eczema. A total of 40 infants with
eczema were randomly divided into treatment and control groups. Prior and subsequent
to the treatment, the SCORAD index was evaluated and the content of Bifidobacterium
bifidum in the stool of each infant in the two groups was quantified using 16S rRNA/DNA
quantitative polymerase chain reaction analysis. After four weeks of treatment with B.
bifidum triple viable capsules, the levels of B. bifidum increased sharply (P<0.05) and the
SCORAD index was notably reduced (P<0.05) as compared with the values prior to
treatment. By contrast, neither the content of B. bifidum nor the SCORAD index changed
significantly in the control group after four weeks (P>0.05). Following treatment, the levels
of B. bifidum in the stools of the treatment group were significantly higher than those in
the stools of the control group (P<0.05), and the SCORAD index was significantly lower
than that of the control group (P<0.05). In conclusion, probiotic supplementation has a
positive effect on the prevention and treatment of infantile eczema.
KEYWORDS:
Bacillus bifidus; eczema; infants; probiotics
Dermatoendocrinol. 2009 Sep;1(5):275-9.

Probiotics for photoprotection.
Guéniche A, Philippe D, Bastien P, Blum S, Buyukpamukcu E, Castiel-Higounenc I.
Abstract
Specific strains of probiotic, have been identified as beneficial to influence the
composition and/or metabolic activity of the endogenous microbiota and some of these
strains have been also shown to inhibit the growth of a wide range of enteropathogens.
The first aim of using probiotics has been to improve the composition of the intestinal
microbiota from a potentially harmful composition towards a composition that would be
beneficial to the host.Beyond their capacity to influence positively the composition of the
intestinal microbiota, several lines of evidence suggest that some probiotic bacteria can
modulate the immune system both at the local and systemic levels thereby improving
immune defense mechanisms and/or downregulate immune disorders such as allergies
or intestinal inflammation.Skin reflects the general health status and aging. Different
human trials widely suggest that probiotic supplementation might be useful in the
management of atopic dermatitis. Based on these properties it appears that, beyond the
gut, probiotics might exert their benefits at the skin level.In a randomized double blind
placebo-controlled clinical trial, we investigated whether the probiotic bacteria
Lactobacillus johnsonii NCC 533 (La1) could modulate the cutaneous immune
homeostasis altered by solar-simulated UV exposure in humans. After, UV exposure to
twice 1.5 MED, we demonstrated that La1 intake facilitated an earlier recovery of
Epidermal cells allostimulatory function. Thus, this clinical data strengthen the assumption
that certain probiotics can contribute to modulate skin immune system leading to the
preservation of the skin homeostasis. Altogether the data affords the possibility of
designing new strategies based on a nutritional approach for the prevention of UV-
induced damaging effects.
KEYWORDS:
Lactobacillus johnsonii; food supplement; immune homeostasis; photoprotection;
probiotics; skin; stress
J Microbiol Biotechnol. 2015 Oct 2. doi: 10.4014/jmb.1509.09021. [Epub ahead of print]
Clinical evidence of effects of Lactobacillus plantarum HY7714 on skin aging: a
randomized, double blind, placebo-controlled study.
Lee DE1, Huh CS2, Ra J1, Choi ID1, Jeong JW1, Kim SH1, Ryu JH3, Seo YK3, Koh JS3,
Lee JH1, Sim JH1, Ahn YT1.
Author information
Abstract
The beneficial effects of probiotics are now widely reported, although there are only a few
studies on their anti-aging effects. We have found that Lactobacillus plantarum HY7714
(HY7714) improves skin hydration and has anti-photoaging effects, and in the present
study, we have further evaluated the anti-aging effect of HY7714 via a randomized,
double blind, placebo-controlled clinical trial. The trial included 110 volunteers aged 41
and 59 years who have dry skin and wrinkles. Participants took 1 × 1010 CFU/day of
HY7714 (probiotic group) or a placebo (placebo group) for 12 weeks. Skin hydration,
wrinkles, skin gloss, and skin elasticity were measured every 4 weeks during the study
period. There were significant increases in the skin water content in the face (p<0.01)
and hands (p<0.05) at week 12 in the probiotic group. Transepidermal water loss
decreased significantly in both groups at weeks 4, 8, and 12 (p<0.001 compared to
baseline), and was suppressed to a greater extent in the face and forearm in the probiotic
group at week 12. Volunteers in the probiotic group had a significant reduction in wrinkle
depth at week 12, and skin gloss was also significantly improved by week 12. Finally, skin
elasticity in the probiotic group improved by 13.17% (p<0.05 vs. controls) after 4 weeks
and by 21.73% (p<0.01 vs. controls) after 12 weeks. These findings are the preliminary
confirmation of the anti-aging benefit to the skin of L. plantarum HY7714 as a
nutricosmetic agent.
KEYWORDS:
Anti-wrinkle; Lactobacillus plantarum; Skin elasticity; Skin gloss; Skin hydration
PMID: 26428734 [PubMed - as supplied by publisher]
Benef Microbes. 2014 Jun 1;5(2):137-45. doi: 10.3920/BM2013.0001.

Randomised double-blind placebo-controlled study of the effect of Lactobacillus
paracasei NCC 2461 on skin reactivity.
Gueniche A1, Philippe D2, Bastien P1, Reuteler G2, Blum S2, Castiel-Higounenc I1,
Breton L1, Benyacoub J2.
Author information
Abstract
In recent decades, the prevalence of subjects with reactive skin has considerably
increased in industrialised countries. 50% of women and 30% of men report cutaneous
discomfort classified under reactive/sensitive skin. Several topical approaches have been
proposed, in particular through improvement of galenic forms or protection of epidermal
surface. We propose to act differently, deeply from inside the body via an innovative
nutritional approach. To this purpose, Lactobacillus paracasei NCC 2461 (ST11) was
selected because of its specific beneficial skin properties discovered in in vitro studies,
i.e. diminution of neurogenic inflammation and promotion of the recovery of skin barrier
function. We designed a randomised double-blind placebo-controlled clinical study with
a two-month supplementation in two female treatment groups (n=32 per group). A
capsaicin test was performed to monitor the time course of skin sensitivity. Moreover,
transepidermal water loss was assessed to analyse the rate of skin barrier function
recovery; dryness of the leg and roughness of the cheeks was investigated by a
dermatologist as well as by self-assessment. The results of the present clinical trial show
that oral supplementation with the probiotic decreases skin sensitivity and increases the
rate of barrier function recovery. Thus, the data provide evidence that daily intake of ST11
could improve reactive skin condition.
KEYWORDS:
Lactobacillus paracasei; barrier function; probiotic; reactive skin
ScientificWorldJournal. 2014 Jan 22;2014:595962. doi: 10.1155/2014/595962.

eCollection 2014.
Effect of probiotics supplementation on bone mineral content and bone mass density.
Parvaneh K1, Jamaluddin R1, Karimi G1, Erfani R2.
Author information
Abstract
A few studies in animals and a study in humans showed a positive effect of probiotic on
bone metabolism and bone mass density. Most of the investigated bacteria were
Lactobacillus and Bifidobacterium. The positive results of the probiotics were supported
by the high content of dietary calcium and the high amounts of supplemented probiotics.
Some of the principal mechanisms include (1) increasing mineral solubility due to
production of short chain fatty acids; (2) producing phytase enzyme by bacteria to
overcome the effect of mineral depressed by phytate; (3) reducing intestinal inflammation
followed by increasing bone mass density; (4) hydrolysing glycoside bond food in the
intestines by Lactobacillus and Bifidobacteria. These mechanisms lead to increase
bioavailability of the minerals. In conclusion, probiotics showed potential effects on bone
metabolism through different mechanisms with outstanding results in the animal model.
The results also showed that postmenopausal women who suffered from low bone mass
density are potential targets to consume probiotics for increasing mineral bioavailability
including calcium and consequently increasing bone mass density.
Eur J Nutr. 2004 Apr;43(2):61-8. Epub 2004 Jan 6.

The effect of Lactobacillus helveticus fermented milk on acute changes in calcium
metabolism in postmenopausal women.
Narva M1, Nevala R, Poussa T, Korpela R.
Author information
Abstract
BACKGROUND:
Milk fermented with Lactobacillus helveticus ( L. helveticus) has been shown to lower
blood pressure and to increase bone mineral content in spontaneously hypertensive rats.
The effect of L.helveticus may be due to better calcium availability.
AIM OF THE STUDY:

In the present study the effect of milk fermented with L. helveticus on acute changes in
calcium metabolism and bone resorption in postmenopausal women was studied.
METHODS:
The study was performed as a randomised double-blind crossover study of 20
postmenopausal women (mean age 65, range 50-78). The study was carried out in two
parts. Firstly, L. helveticus fermented milk was compared to a control milk. Secondly,
juice containing peptides formed with L. helveticus bacteria was compared to a control
juice. The acute effect on calcium metabolism was measured during the study day by
serum ionised calcium (iCa), parathyroid hormone (PTH), calcium (Ca), phosphate (P),
and urinary calcium. A direct marker of bone turnover, carboxyterminal telopeptide of type
I collagen (ICTP), was measured from the serum.
RESULTS:
L. helveticus fermented milk reduced serum PTH (405.3 +/- 37 ng/l vs. 454.9 +/- 37, p
= 0.012) and increased serum calcium (19.1 +/- 0.2 mmol/l vs. 18.8 +/- 0.2, p = 0.031)
compared to the control milk. L. helveticus derived peptides had no significant acute
effect on calcium metabolism, in fact, ionised calcium was lower and PTH higher after the
juice containing peptides compared to the control juice.
CONCLUSIONS:
Fermentation of milk with Lactobacillus helveticus had a positive acute effect on calcium
metabolism. This effect was not explained by the small peptides formed by L. helveticus.
Nutrition. 2014 Apr;30(4):430-5. doi: 10.1016/j.nut.2013.09.007. Epub 2013 Dec 17.

Probiotic supplementation improves inflammatory status in patients with rheumatoid
arthritis.
Vaghef-Mehrabany E1, Alipour B2, Homayouni-Rad A3, Sharif SK4, Asghari-Jafarabadi
M5, Zavvari S6.
Author information
Abstract
OBJECTIVES:
Rheumatoid arthritis (RA) is an inflammatory autoimmune disease in which the gut
microbiota is altered. Probiotics are microorganisms that can normalize gut microbiota;
thus, they may help to alleviate RA symptoms. The objective of the present clinical trial
was to assess the effects of probiotic supplementation on disease activity and
inflammatory cytokines in patients with RA.
METHODS:
Forty-six patients with RA were assigned into two groups in this randomized, double-
blind, placebo-controlled clinical trial. The patients in the probiotic group received a daily
capsule that contained a minimum of 10(8) colony-forming units of Lactobacillus casei 01
for 8 wk. The placebo group took capsules filled with maltodextrin for the same time
period. Questionnaires, anthropometric measurements, and fasting blood samples were
collected, and the participants were assessed by a rheumatologist at baseline and at the
end of the trial.
RESULTS:
Disease activity score was significantly decreased by the intervention, and there was a
significant difference between the two groups at the end of the study (P < 0.01). Three of
the assessed serum proinflammatory cytokines (tumor necrosis factor-α, interleukin-6,
and interleukin-12) significantly decreased in the probiotic group (P < 0.05); however,
serum levels of interleukin-1 β were not significantly affected by the probiotic (P = 0.22).
The serum level of regulatory cytokine (interleukin-10) was increased by the
supplementation (P < 0.05). The proportion of interleukin-10 to interleukin-12 was
significantly increased in the probiotic group as well.
CONCLUSIONS:
L. casei 01 supplementation improved the disease activity and inflammatory status of
patients with RA. Further studies are warranted to confirm these results, and such
confirmation may lead to the introduction of probiotics as adjunctive therapy for this
population.
Copyright © 2014 Elsevier Inc. All rights reserved.
KEYWORDS:
Cytokines; Disease activity; Inflammation; Lactobacillus casei 01; Randomized clinical
trial; Rheumatoid arthritis
Int J Rheum Dis. 2014 Jun;17(5):519-27. doi: 10.1111/1756-185X.12333. Epub 2014 Mar
27.
Effects of Lactobacillus casei supplementation on disease activity and inflammatory
cytokines in rheumatoid arthritis patients: a randomized double-blind clinical trial.
Alipour B1, Homayouni-Rad A, Vaghef-Mehrabany E, Sharif SK, Vaghef-Mehrabany L,
Asghari-Jafarabadi M, Nakhjavani MR, Mohtadi-Nia J.
Author information
Abstract
AIM:
The present study aimed at investigating the effects of Lactobacillus casei 01
supplementation on symptoms and inflammatory biomarkers of rheumatoid arthritis (RA)
in women.
METHOD:
In this randomized double-blind clinical trial, female patients with established RA for more
than 1 year, 20-80 years of age and body mass index (BMI) lower than 40, who followed
stable medication for 3 months prior to the supplementation, were randomly allocated to
receive either one capsule containing 10(8) colony forming units (CFU) of L. casei 01, or
a placebo for 8 weeks; allocation was stratified by BMI and menopausal status. Disease
activity score-28 (DAS28) was calculated, European League Against Rheumatism
(EULAR) response was evaluated and the cytokines, interleukin (IL)-1β, IL-6, IL-10, IL-12
and tumor necrosis factor (TNF)-α were measured.
RESULTS:
Thirty patients were recruited in each group; 22 and 24 patients were analyzed in the
probiotic and placebo groups, respectively. L. casei 01 supplementation decreased
serum high-sensitivity C-reactive protein (hs-CRP) levels, tender and swollen joint counts,
global health (GH) score and DAS28 (P < 0.05). More patients in the L. casei 01 group
had moderate response to the treatment, based on the EULAR criteria, at the end of the
study (P < 0.01). At the end of the study, a significant difference was observed between
the two groups for IL-10, IL-12 and TNF-α changes through the study course (P < 0.05),
in favor of the probiotic group. No adverse effects were reported for the intervention.
CONCLUSION:
Probiotic supplementation may be an appropriate adjunct therapy for RA patients and
help alleviate symptoms and improve inflammatory cytokines.
© 2014 Asia Pacific League of Associations for Rheumatology and Wiley Publishing Asia
Pty Ltd.
KEYWORDS:
DAS28; EULAR criteria; inflammatory cytokines; probiotics; rheumatoid arthritis
Comment in
Rheumatic diseases and the microbiome. [Int J Rheum Dis. 2014]
Eur J Clin Nutr. 2014 May;68(5):602-7. doi: 10.1038/ejcn.2014.13. Epub 2014 Feb 26.
Efficacy and safety of the probiotic Lactobacillus paracasei LP-33 in allergic rhinitis: a
double-blind, randomized, placebo-controlled trial (GA2LEN Study).
Costa DJ1, Marteau P2, Amouyal M1, Poulsen LK3, Hamelmann E4, Cazaubiel M5,
Housez B5, Leuillet S5, Stavnsbjerg M6, Molimard P7, Courau S7, Bousquet J8.
Author information
Abstract
BACKGROUND/OBJECTIVES:
An imbalance between Th1 and Th2 cells is involved in allergic rhinitis (AR) that may be
improved by probiotics. To test the efficacy of the probiotic Lactobacillus paracasei
subsp. paracasei LP-33, a double-blind, placebo-controlled, randomized trial was carried
out in patients with AR to grass pollen treated with loratadine and presenting altered
quality of life.
SUBJECTS/METHODS:
Subjects with persistent AR, symptomatic during the grass pollen season, and a positive
skin test or specific immunoglobulin E to grass pollens were included by general
practitioners (GPs). All received loratadine for 5 weeks. The primary end point was the
improvement in Rhinitis Quality of Life (RQLQ) global score at the fifth week of LP-33
consumption compared with placebo (in addition to loratadine). Secondary end points
included nasal and ocular symptoms (individual and total symptom scores), visual
analogue scale and time of first exacerbation of the symptoms when loratadine was
stopped.
RESULTS:
A total of 425 subjects were included. Using intent-to-treat analysis, the RQLQ global
score decreased significantly more in the LP-33 group than in the placebo group
(P=0.0255, difference=-0.286 (95% confidence interval (CI): -0.536; -0.035)). No
significant differences were noted for the change of the rhinitis total symptom score 5
global score between groups (P=0.1288, difference=-0.452 (95% CI: -1.036; 0.132)).
Significant differences in ocular symptoms (RQLQ) were observed between groups
(P=0.0029, difference=-0.4087 (95% CI: -0.6768; -0.1407)).
CONCLUSIONS:
This study performed by GPs shows that LP-33 improves the quality of life of subjects
with persistent AR who are currently being treated with an oral H1-antihistamine. Whereas
nasal symptoms had not changed, ocular symptoms had consistently improved.
Eur J Clin Nutr. 2013 Feb;67(2):161-7. doi: 10.1038/ejcn.2012.197. Epub 2013 Jan 9.
Immune-modulatory effect of probiotic Bifidobacterium lactis NCC2818 in individuals
suffering from seasonal allergic rhinitis to grass pollen: an exploratory, randomized,
placebo-controlled clinical trial.
Singh A1, Hacini-Rachinel F, Gosoniu ML, Bourdeau T, Holvoet S, Doucet-Ladeveze R,
Beaumont M, Mercenier A, Nutten S.
Author information
Abstract
BACKGROUND/OBJECTIVES:
Probiotics are defined as 'living micro-organisms that when administered in adequate
amounts confer a health benefit to the host'. Different probiotic strains have been
investigated for beneficial effects on allergic disorders. The purpose of the current study
was to evaluate the effect of orally administering the probiotic Nestlé culture collection
(NCC)2818 Bifidobacterium lactis strain on immune parameters and nasal symptom
scores in subjects suffering from seasonal allergic rhinitis (SAR).
SUBJECTS/METHODS:
The study was a double-blinded, parallel, randomized placebo-controlled trial conducted
during the peak of the pollen season. Adult subjects with clinical history of SAR and
positive skin prick test to grass pollen were recruited. The subjects received B. lactis
NCC2818 or placebo for 8 weeks and completed symptom questionnaires every week.
Whole blood was collected at baseline (V1), 4 weeks (V2) and 8 weeks (V3) to measure
immune parameters.
RESULTS:
Concentrations of Th-2 cytokines, secreted by stimulated blood lymphocytes, were
significantly lower in the probiotic group compared with the placebo group at V3
(interleukin (IL)-5, P=0.016; IL-13, P=0.005). Total nasal symptom scores were
significantly lower in the second month of the study (weeks 5-8) in the probiotic group
compared with the placebo group (P=0.03). Also, percentages of activated CD63
expressing basophils were significantly lower in the probiotic group at V2 (P=0.02).
CONCLUSIONS:
Oral administration of the probiotic NCC2818 mitigates immune parameters and allergic
symptoms during seasonal exposure. These promising results warrant that B. lactis
NCC2818 be investigated further in large-scale trials for management of respiratory
allergy.
Eur J Clin Nutr. 2002 Dec;56(12):1155-61.

Effects of dietary yoghurt on immunological and clinical parameters of rhinopathic
patients.
Aldinucci C1, Bellussi L, Monciatti G, Passàli GC, Salerni L, Passàli D, Bocci V.
Author information
Abstract
OBJECTIVES:
To examine the immunological and clinical influence of 4 months' feeding with either
yoghurt or partially skimmed milk or nothing, on 20 volunteers.
SUBJECTS:
Thirteen subjects had a demonstrated allergic rhinopathy and seven were healthy
subjects and participated as controls.
RESEARCH DESIGN:
Either a group of seven or a group of six rhinopathic patients were fed either 450 g
yoghurt or 450 g partially skimmed milk, respectively, for 4 months between March and
October 1999. All subjects maintained their usual diet throughout the study. Peripheral
blood mononuclear cells (PBMC) were isolated before and after the experimental period
and cultured for periods of 40 and 64 h. Proliferation index assay and release of
IFNgamma and IL-4 without and with PHA stimulation were assessed. Allergic rhinopathy
was evaluated before and after the 4 months period by performing the nasal functionality
tests (Active Anterior Rhinomanometry, Acoustic Rhinometry), the prick test, the nasal
specific provocation test (NPT), the dosage of specific IgE blood levels, the evaluation of
the symptomatological score and the nasal mucociliary transport test.
RESULTS:
No significant change of the proliferation index was noted among the three groups.
Cultured PBMC of the group fed with yoghurt released more IFNgamma and less IL-4.
Cytokine plasma levels were at and remained at basal levels. Prick test, specific serum
IgEs and NPT remained immodified. Muco-ciliary transport time (MCTt) and
symptomatological score showed a definitive improvement after yoghurt feeding.
CONCLUSION:
Yoghurt feeding appears to improve or prevent allergic recurrences in rhinopatic patients.
Pediatr Pulmonol. 2010 Nov;45(11):1111-20. doi: 10.1002/ppul.21296.

Randomized placebo-controlled trial of lactobacillus on asthmatic children with allergic
rhinitis.
Chen YS1, Jan RL, Lin YL, Chen HH, Wang JY.
Author information
Abstract
Previous studies have suggested that probiotic administration may have therapeutic
and/or preventive effects on atopic dermatitis in infants; however, its role in allergic airway
diseases remains controversial. To determine whether daily supplementation with specific
Lactobacillus gasseri A5 for 8 weeks can improve the clinical symptoms and
immunoregulatory changes in school children suffering from asthma and allergic rhinitis
(AR). We conducted a randomized, double-blind, placebo-controlled study on school
children (age, 6-12 years) with asthma and AR. The eligible study subjects received either
L. gasseri A5 (n = 49) or a placebo (n = 56) daily for 2 months. Pulmonary function tests
were performed, and the clinical severity of asthma and AR was evaluated by the
attending physicians in the study period. Diary cards with records of the day- and
nighttime peak expiratory flow rates (PEFR), symptoms of asthma, and AR scores of the
patients were used for measuring the outcome of the treatment. Immunological
parameters such as the total IgE and cytokine production by the peripheral blood
mononuclear cells (PBMCs) were determined before and after the probiotic treatments.
Our results showed the pulmonary function and PEFR increased significantly, and the
clinical symptom scores for asthma and AR decreased in the probiotic-treated patients
as compared to the controls. Further, there was a significant reduction in the TNF-α, IFN-
γ, IL-12, and IL-13 production by the PBMCs following the probiotic treatment. In
conclusion, probiotic supplementation may have clinical benefits for school children
suffering from allergic airway diseases such as asthma and AR.
Comment in
Therapeutic role of probiotics in asthma and allergic rhinitis. [Pediatr Pulmonol. 2012]
Pediatr Res. 2007 Aug;62(2):215-20.

A randomized prospective double blind controlled trial on effects of long-term
consumption of fermented milk containing Lactobacillus casei in pre-school children with
allergic asthma and/or rhinitis.
Giovannini M1, Agostoni C, Riva E, Salvini F, Ruscitto A, Zuccotti GV, Radaelli G; Felicita
Study Group.
Author information
Abstract
To examine whether long-term consumption of fermented milk containing a specific
Lactobacillus casei may improve the health status of preschool children suffering from
allergic asthma and/or rhinitis a randomized, prospective, double blind, controlled trial
was conducted in 187 children 2-5 y of age. The children received for 12 mo either
fermented milk (100 mL) containing Lactobacillus casei (10(8) cfu/mL) or placebo. The
time free from and the number of episodes of asthma/rhinitis after starting intervention
were the outcome measures. The number of fever or diarrhea episodes and the change
in serum immunoglobulin were further assessed. No statistical difference between
intervention and control group occurred in asthmatic children. In children with rhinitis, the
annual number of rhinitis episodes was lower in the intervention group, mean difference
(95% CI), -1.6 (-3.15 to -0.05); the mean duration of an episode of diarrhea was lower in
the intervention group, mean difference -0.81 (-1.52 to -0.10) days. While long-term
consumption of fermented milk containing Lactobacillus casei may improve the health
status of children with allergic rhinitis no effect was found in asthmatic children.
Georgian Med News. 2013 Jun;(219):46-52.

[Effect of probiotics on the dynamics of gastrointestinal symptoms of food allergy to
cow's milk protein in infants].
[Article in Russian]
Ivakhnenko ES, Nian'kovskiĭ SL.
Abstract
The problem of food allergy to cow's milk protein in children is highly important. The aim
of this study was to estimate the effect of Bifidobacterium lactis BB-12 (1х109 CFU) and
Streptococcus thermophilus TH-4 (1х108 CFU) administration on gastrointestinal
symptoms of cow's milk allergy in infants. We conducted an open randomized
prospective clinical study. 60 infants aged of 3-12 months with the diagnosis of atopic
dermatitis and allergy to cow's milk protein were enrolled. Children were divided into 2
groups, one of which received probiotics during 4 weeks. Results were estimated after 4
and 8 weeks of study. We found significant impact on reducing the frequency of
constipation in infants who received the probiotics in complex treatment. After 4 weeks of
treatment constipation was absent in 85.71% infants who received probiotics as
compared to 48.15% in the control group (р=0.02), after 8 weeks the same numbers
were 92.86% vs. 62.96% accordingly (p=0.04). Significant differences between the
groups were also determined by the incidences of infantile colic through 4 and 8 weeks
and on diarrhea through 8 weeks of studies. It is possible to draw a conclusion that
administration of probiotics in addition to elimination diet and base treatment to infants
with atopic dermatitis and cow's milk allergy improves clinical symptoms of the disease
and decreases gastrointestinal clinical manifestations of cow's milk allergy.
Allergol Int. 2014 Dec;63(4):575-85. doi: 10.2332/allergolint.13-OA-0683. Epub 2014 Jul

25.
Effects of bifidobacterial supplementation to pregnant women and infants in the
prevention of allergy development in infants and on fecal microbiota.
Enomoto T1, Sowa M2, Nishimori K2, Shimazu S3, Yoshida A4, Yamada K5, Furukawa
F6, Nakagawa T7, Yanagisawa N8, Iwabuchi N9, Odamaki T9, Abe F9, Nakayama J10,
Xiao JZ9.
Author information
Abstract
BACKGROUND:
Probiotic administration may be a useful method for preventing allergies in infants;
however, there have been controversial results about the efficacy. We investigated the
effects of bifidobacterial supplementation on the risk of developing allergic diseases in
the Japanese population.
METHODS:
In an open trial, we gave Bifidobacterium breve M-16V and Bifidobacterium longum
BB536 prenatally to 130 mothers beginning 1 month prior to delivery and postnatally to
their infants for 6 months. Another 36 mother-infant pairs served as controls and did not
receive the bifidobacterial supplementation. Development of allergic symptoms in the
infants was assessed at 4, 10 and 18 months of age. Fecal samples were collected from
the mothers and infants.
RESULTS:
The risk of developing eczema/atopic dermatitis (AD) during the first 18 months of life
was significantly reduced in infants in the probiotic group (OR: 0.231 [95% CI: 0.084-
0.628] and 0.304 [0.105-0.892] at 10 and 18 months of age, respectively).
Pyrosequencing analyses indicated an altered composition of the fecal microbiota at 4
months for infants who developed eczema/AD at 4 and 10 months of age. The
proportion of Proteobacteria was significantly lower (P = 0.007) in mothers at the time of
delivery who received the supplementation when compared with the control group and
was positively correlated (r = 0.283, P = 0.024) with that of infants at 4 months of age.
No adverse effects were related to the use of probiotics.
CONCLUSIONS:
These data suggest that the prenatal and postnatal supplementation of bifidobacteria is
effective in primary preventing allergic diseases. Some limited changes in the
composition of fecal microbiota by the bifidobacterial supplementation were observed.
Can J Microbiol. 2009 Feb;55(2):133-8. doi: 10.1139/w08-102.

Improved cure of bacterial vaginosis with single dose of tinidazole (2 g), Lactobacillus
rhamnosus GR-1, and Lactobacillus reuteri RC-14: a randomized, double-blind,
placebo-controlled trial.
Martinez RC1, Franceschini SA, Patta MC, Quintana SM, Gomes BC, De Martinis EC,
Reid G.
Author information
Abstract
Bacterial vaginosis (BV) is the most prevalent vaginal infection worldwide and is
characterized by depletion of the indigenous lactobacilli. Antimicrobial therapy is often
ineffective. We hypothesized that probiotic Lactobacillus rhamnosus GR-1 and
Lactobacillus reuteri RC-14 might provide an adjunct to antimicrobial treatment and
improve cure rates. Sixty-four Brazilian women diagnosed with BV were randomly
assigned to receive a single dose of tinidazole (2 g) supplemented with either 2 placebo
capsules or 2 capsules containing L. rhamnosus GR-1 and L. reuteri RC-14 every
morning for the following 4 weeks. At the end of treatment (day 28), the probiotic group
had a significantly higher cure rate of BV (87.5%) than the placebo group (50.0%) (p =
0.001). In addition, according to the Gram-stain Nugent score, more women were
assessed with "normal" vaginal microbiota in the probiotic group (75.0% vs. 34.4% in the
placebo group; p = 0.011). This study shows that probiotic lactobacilli can provide
benefits to women being treated with antibiotics for an infectious condition.
BJOG. 2008 Oct;115(11):1369-74. doi: 10.1111/j.1471-0528.2008.01882.x.
The role of Lactobacillus casei rhamnosus Lcr35 in restoring the normal vaginal flora after
antibiotic treatment of bacterial vaginosis.
Petricevic L1, Witt A.
Author information
Abstract
OBJECTIVE:
To evaluate the efficacy of additional topical Lactobacillus casei rhamnosus (Lcr35)
subsequent to antibiotic treatment of bacterial vaginosis (BV) to restore the normal vaginal
flora.
STUDY DESIGN:
Single-centre, randomised, observerblinded study.
SETTING:
Population-based study in Vienna over 1 year.
SAMPLE:
190 women were enrolled in the study.
METHODS:
Women with Nugent scores between 7 and 10 on initial vaginal swab were randomised
to the one of two groups. All women were treated with standard antibiotic therapy for 7
days. Only women in the intervention group received vaginal capsules containing 10(9)
colony-forming units of live Lcr35 for 7 days after antibiotic treatment. Final vaginal swabs
for Nugent scoring were taken 4 weeks after the last administration of the study
medication.
MAIN OUTCOME MEASURES:

The primary efficacy variable was a change in the Nugent score between the baseline
and the end of the study of at least 5 grades in each individual woman.
RESULTS:
Sixty-nine of the 83 women (83%) in the intervention group and 31 of the 88 women (35%)
in the control group showed a reduction of the Nugent score by at least 5 grades. The
difference in the number of women with improvement was highly significant (P < 0.001).
The median difference in Nugent scores between initial and final swabs was 6.61 in the
intervention group and 4.13 in the control group (P < 0.001).
CONCLUSION:
Our data show that the restoration of the vaginal flora after antibiotic treatment of BV can
be significantly enhanced by exogenously applied lactobacilli.
Lett Appl Microbiol. 2009 Mar;48(3):269-74. doi: 10.1111/j.1472-765X.2008.02477.x.
Epub 2009 Feb 2.
Improved treatment of vulvovaginal candidiasis with fluconazole plus probiotic
Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14.
Martinez RC1, Franceschini SA, Patta MC, Quintana SM, Candido RC, Ferreira JC, De
Martinis EC, Reid G.
Author information
Abstract
AIMS:
To determine the ability of probiotic lactobacilli to improve the treatment of vulvovaginal
candidiasis (VVC) using a randomized, double-blind and placebo-controlled trial.
METHODS AND RESULTS:

Fifty-five women diagnosed with VVC by vaginal discharge positive for Candida spp.
(according to culture method) associated with at least one of the symptoms (itching and
burning vaginal feeling, dyspareunia and dysuria), were treated with single dose of
fluconazole (150 mg) supplemented every morning for the following 4 weeks with two
placebo or two probiotic capsules (containing Lactobacillus rhamnosus GR-1 and
Lactobacillus reuteri RC-14). At 4 weeks, the probiotic treated group showed significantly
less vaginal discharge associated with any of the above mentioned symptoms (10.3%vs
34.6%; P = 0.03) and lower presence of yeast detected by culture (10.3%vs 38.5%; P =
0.014).
CONCLUSION:
This study has shown that probiotic lactobacilli can increase the effectiveness of an anti-
fungal pharmaceutical agent in curing disease.
SIGNIFICANCE AND IMPACT OF THE STUDY:

This novel finding of probiotic lactobacilli augmenting the cure rate of yeast vaginitis, not
only offers an alternative approach to a highly prevalent condition that adversely affects
the quality of life of women around the world, but also raises the question of how this
combination works.
Arch Gynecol Obstet. 2014 Mar;289(3):601-8. doi: 10.1007/s00404-013-3030-6. Epub

2013 Sep 22.
Triple therapy with Lactobacilli acidophili, estriol plus pelvic floor rehabilitation for
symptoms of urogenital aging in postmenopausal women.
Capobianco G1, Wenger JM, Meloni GB, Dessole M, Cherchi PL, Dessole S.
Author information
Abstract
PURPOSE:
To assess the effects of the combination of pelvic floor rehabilitation, intravaginal estriol
and Lactobacillus acidophli administration on stress urinary incontinence (SUI), urogenital
atrophy and recurrent urinary tract infections in postmenopausal women.
METHODS:
136 postmenopausal women with urogenital aging symptoms were enrolled in this
prospective randomized study.
PATIENTS:
randomly divided into two groups and each group consisted of 68 women.
INTERVENTIONS:
Subjects in the triple therapy (group I) received 1 intravaginal ovule containing 30 mcg
estriol and Lactobacilli acidophili (50 mg lyophilisate containing at least 100 million live
bacteria) such as once daily for 2 weeks and then two ovules once weekly for a total of 6
months as maintenance therapy plus pelvic floor rehabilitation. Subjects in the group II
received one intravaginal estriol ovule (1 mg) plus pelvic floor rehabilitation in a similar
regimen.
MEAN OUTCOME MEASURES:

We evaluated urogenital symptomatology, urine cultures, colposcopic findings, urethral
cytologic findings, urethral pressure profiles and urethrocystometry before, as well as after
6 months of treatment.
RESULTS:
After therapy, the symptoms and signs of urogenital atrophy significantly improved in both
groups. 45/59 (76.27%) of the group I and 26/63 (41.27%) of the group II referred a
subjective improvement of their incontinence. In the patients treated by triple therapy with
lactobacilli, estriol plus pelvic floor rehabilitation, we observed significant improvements of
colposcopic findings, and there were statistically significant increases in mean maximum
urethral pressure, in mean urethral closure pressure, as well as in the abdominal pressure
transmission ratio to the proximal urethra.
CONCLUSIONS:
Our results showed that triple therapy with L. acidophili, estriol plus pelvic floor
rehabilitation was effective and should be considered as first-line treatment for symptoms
of urogenital aging in postmenopausal women.
Eur J Obstet Gynecol Reprod Biol. 2008 Nov;141(1):54-7. doi:

10.1016/j.ejogrb.2008.06.003. Epub 2008 Aug 12.
Randomized, double-blind, placebo-controlled study of oral lactobacilli to improve the
vaginal flora of postmenopausal women.
Petricevic L1, Unger FM, Viernstein H, Kiss H.
Author information
Abstract
OBJECTIVE:
The purpose of this randomized, double-blind, placebo-controlled study was to evaluate
the influence of the orally administered probiotic strains Lactobacillus rhamnosus GR-1
and Lactobacillus reuteri RC-14 on the quality of the vaginal flora in postmenopausal
women.
STUDY DESIGN:
Postmenopausal women with Nugent scores between 4 and 6 in initial vaginal swab,
were randomized into two groups. Women in the intervention group received probiotic
capsules containing 2.5x10(9)CFU (colony forming units) each of lyophilized L.
rhamnosus GR-1 and L. reuteri RC-14 and women in the control group received an oral
placebo once daily, in both groups for 14 days. Final vaginal swabs were taken 1 day
after the last administration of the medication. The primary efficacy variable was a change
in the Nugent score between baseline and the end of the study of at least two grades in
each individual patient.
RESULTS:
Seventy two women were recruited in the study, 35 assigned to the intervention group
and 37 to the control group. Twenty-one of the 35 subjects (60%) in the intervention
group and 6 of the 37 subjects (16%) in the control group showed a reduction in the
Nugent score by at least two grades. The difference in the number of patients with
improvement was highly significant (p=0.0001). The median difference in Nugent scores
between baseline and the end of the study was 3 in the intervention group and 0 in the
control group (p=0.0001).
CONCLUSION:
Our results provide evidence for an alternative modality to restore the normal vaginal flora
using specific probiotic strains administered orally.
Brain Behav Immun. 2015 Aug;48:258-64. doi: 10.1016/j.bbi.2015.04.003. Epub 2015

Apr 7.
A randomized controlled trial to test the effect of multispecies probiotics on cognitive
reactivity to sad mood.
Steenbergen L1, Sellaro R2, van Hemert S3, Bosch JA4, Colzato LS5.
Author information
Abstract
BACKGROUND:
Recent insights into the role of the human microbiota in cognitive and affective
functioning have led to the hypothesis that probiotic supplementation may act as an
adjuvant strategy to ameliorate or prevent depression.
OBJECTIVE:
Heightened cognitive reactivity to normal, transient changes in sad mood is an
established marker of vulnerability to depression and is considered an important target for
interventions. The present study aimed to test if a multispecies probiotic containing
Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Lactobacillus acidophilus W37,
Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, and
Lactococcus lactis (W19 and W58) may reduce cognitive reactivity in non-depressed
individuals.
DESIGN:
In a triple-blind, placebo-controlled, randomized, pre- and post-intervention assessment
design, 20 healthy participants without current mood disorder received a 4-week
probiotic food-supplement intervention with the multispecies probiotics, while 20 control
participants received an inert placebo for the same period. In the pre- and post-
intervention assessment, cognitive reactivity to sad mood was assessed using the
revised Leiden index of depression sensitivity scale.
RESULTS:
Compared to participants who received the placebo intervention, participants who
received the 4-week multispecies probiotics intervention showed a significantly reduced
overall cognitive reactivity to sad mood, which was largely accounted for by reduced
rumination and aggressive thoughts.
CONCLUSION:
These results provide the first evidence that the intake of probiotics may help reduce
negative thoughts associated with sad mood. Probiotics supplementation warrants
further research as a potential preventive strategy for depression.
Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.
KEYWORDS:
Cognitive reactivity; Depression; Probiotics
PMID: 25862297 [PubMed - in process] Free full text

Super Formulário Probióticos Bifórmula PDF

Enviado por

Dados do documento

Título original

Direitos autorais

Formatos disponíveis

Compartilhar este documento

Compartilhar ou incorporar documento

Opções de compartilhamento

Você considera este documento útil?

Este conteúdo é inapropriado?

Direitos autorais:

Formatos disponíveis

Super Formulário Probióticos Bifórmula PDF

Enviado por

Direitos autorais:

Formatos disponíveis

Índice

Autores consideram que o termo probiótico se aplica a culturas únicas ou

Principais Características dos Probióticos

 Devem estar em quantidades adequadas, alterando assim a microbiota própria

Aplicações e Mecanismos de Ação

Tratamento e prevenção de doenças, regulação da

Indivíduos com constipação crônica foram selecionados e divididos em 2 grupos

 A resposta clínica favorável foi avaliada através do escore Agachan, o qual

 Os indivíduos do grupo tratamento também apresentaram redução do tempo de

A administração de um iogurte enriquecido com uma mistura de probióticos +

Nesse estudo, 31 pacientes sob terapia com antibióticos foram selecionados

Entre os parâmetros avaliados, estavam a consistência das fezes, a frequência de evacuações e

 Os principais problemas de saúde apresentados pelos pacientes eram:

A suplementação com probióticos é uma estratégica segura e eficaz para prevenir a

 A duração média da diarreia foi significativamente inferior no grupo tratado com

Um total de 52 crianças com cólica, de acordo com o critério Wessel

 As crianças tratadas com probióticos apresentaram redução do choro e da

Um total de 50 pacientes com síndrome do intestino irritável com

 A proporção de pacientes com alívio dos sintomas foi significativamente maior no

Pool de Probióticos Reduz os Sintomas da SII em 68% dos Pacientes

De acordo com os resultados, a suplementação com probióticos promoveu redução da

Outras Evidências Encontradas

Existem muitos estudos clínicos que investigam os benefícios terapêuticos dos

Um total de 10 pacientes com Doença de Crohn, cujos principais sintomas eram

 A duração do estudo foi de 13 +/- 4,5 meses;

Um total de 187 pacientes com colite ulcerativa foram selecionados para

Grupo I (n=65) Grupo II (n=60) Grupo III (n=62)

 O índice de atividade da doença, endoscopia e escores histológicos foram determinados no

 A análise global não mostrou nenhuma diferença significativa na taxa de recaída

 No entanto, o tratamento com L. rhamnosus isolado mostrou ser mais eficaz do

Os resultados do estudo demonstraram que a suplementação de L. rhamnosus parece ser

Um total de 22 pacientes com colite ulcerativa foi selecionado para participar

 A suplementação com B. infantis resultou na diminuição dos níveis plasmáticos

 Os níveis de interleucina-6 (IL-6) também foram reduzidos com a suplementação

Os resultados demonstraram a capacidade de B. infantis em

Avaliar os efeitos de um pool de probióticos administrados no período pós-operatório

Pacientes idosos submetidos à cirurgia colorretal laparoscópica foram

*Os pacientes do grupo I receberam uma mistura diária de probióticos, dividida em 2

 Os pacientes do grupo I apresentaram melhora do trânsito intestinal, com

Noventa pacientes dispépticos, H. pylori positivos foram submetidos a 2

Protocolo 2 - Duração 10 dias

*Inibidor de bomba protônica.

 A taxa de erradicação foi significativamente maior no grupo que recebeu a terapia

Hauser et al. (2015) conduziram um estudo para avaliar a eficácia da associação de

 Os resultados demonstraram que houve maior taxa de cura dos indivíduos no

Lactobacillus acidophilus.....1 x 109 UFC

Administrar 1 sachê ao dia ou conforme orientação

Prevenção/Tratamento da Diarreia Associada à Antibioticoterapia

Cápsulas de Lactobacillus reuteri

Lactobacillus reuteri..............1 x 109 UFC

Administrar 2 cápsulas ao dia ou conforme orientação

Tratamento da Diarreia Aguda em Crianças

Iogurte Enriquecido com Probióticos

Lactobacillus casei..............10 x 109 UFC

Administrar 1 sachê ao dia ou conforme orientação

Tratamento da Cólica em Crianças

Cápsulas com L. reuteri

Lactobacillus reuteri..............1 x 108 UFC

Administrar 1 cápsula ao dia ou conforme orientação

Lactobacillus acidophilus.......3,5 x 109 UFC

Administrar 1 sachê ao dia ou conforme orientação

Dose diária ou conforme orientação médica/nutricional.

Lactobacillus plantarum............5 x 107 UFC